NO330692B1 - 4-substituerte imidazol-2-tioner og imidazol-2-oner for behandling av sykdom samt anvendelse av disse for fremstilling av medikament for behandling av sykdom - Google Patents
4-substituerte imidazol-2-tioner og imidazol-2-oner for behandling av sykdom samt anvendelse av disse for fremstilling av medikament for behandling av sykdom Download PDFInfo
- Publication number
- NO330692B1 NO330692B1 NO20045054A NO20045054A NO330692B1 NO 330692 B1 NO330692 B1 NO 330692B1 NO 20045054 A NO20045054 A NO 20045054A NO 20045054 A NO20045054 A NO 20045054A NO 330692 B1 NO330692 B1 NO 330692B1
- Authority
- NO
- Norway
- Prior art keywords
- carbon atoms
- compound
- mmol
- dihydro
- mixture
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 201000010099 disease Diseases 0.000 title abstract description 11
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 291
- 208000002193 Pain Diseases 0.000 claims abstract description 61
- 230000036407 pain Effects 0.000 claims abstract description 30
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 claims abstract description 16
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 claims abstract description 16
- 241000124008 Mammalia Species 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 297
- 125000004432 carbon atom Chemical group C* 0.000 claims description 76
- 229920006395 saturated elastomer Polymers 0.000 claims description 47
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
- -1 C1-6dialkylamino Chemical group 0.000 claims description 28
- 229910052801 chlorine Inorganic materials 0.000 claims description 27
- 229910052794 bromium Inorganic materials 0.000 claims description 26
- 208000000094 Chronic Pain Diseases 0.000 claims description 24
- 229910052731 fluorine Inorganic materials 0.000 claims description 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 23
- 229910052740 iodine Inorganic materials 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 15
- 230000004770 neurodegeneration Effects 0.000 claims description 14
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 208000010412 Glaucoma Diseases 0.000 claims description 10
- 208000004454 Hyperalgesia Diseases 0.000 claims description 10
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 206010053552 allodynia Diseases 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 208000004296 neuralgia Diseases 0.000 claims description 9
- 208000021722 neuropathic pain Diseases 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 208000009935 visceral pain Diseases 0.000 claims description 9
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 8
- 229910006069 SO3H Inorganic materials 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 8
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 7
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 208000007882 Gastritis Diseases 0.000 claims description 7
- 206010028735 Nasal congestion Diseases 0.000 claims description 7
- 208000006011 Stroke Diseases 0.000 claims description 7
- 230000036506 anxiety Effects 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 7
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 7
- 201000006549 dyspepsia Diseases 0.000 claims description 7
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 7
- 206010025135 lupus erythematosus Diseases 0.000 claims description 7
- 208000031225 myocardial ischemia Diseases 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 6
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 6
- 208000028698 Cognitive impairment Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 206010012735 Diarrhoea Diseases 0.000 claims description 6
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims description 6
- 201000005569 Gout Diseases 0.000 claims description 6
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims description 6
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 6
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 6
- 208000004880 Polyuria Diseases 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 201000002661 Spondylitis Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 230000035619 diuresis Effects 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 208000028867 ischemia Diseases 0.000 claims description 6
- 206010027175 memory impairment Diseases 0.000 claims description 6
- 208000020911 optic nerve disease Diseases 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 206010061323 Optic neuropathy Diseases 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 230000004406 elevated intraocular pressure Effects 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 101100134929 Gallus gallus COR9 gene Proteins 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 125000004001 thioalkyl group Chemical group 0.000 claims 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 208000035475 disorder Diseases 0.000 abstract description 18
- 239000000556 agonist Substances 0.000 abstract description 17
- 230000001624 sedative effect Effects 0.000 abstract description 9
- 230000005792 cardiovascular activity Effects 0.000 abstract description 4
- 239000000543 intermediate Substances 0.000 description 284
- 239000000203 mixture Substances 0.000 description 215
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 167
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 151
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 149
- 239000000243 solution Substances 0.000 description 147
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 99
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 87
- 235000019439 ethyl acetate Nutrition 0.000 description 78
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 71
- 238000004587 chromatography analysis Methods 0.000 description 64
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 62
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 59
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 56
- 239000012267 brine Substances 0.000 description 52
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 52
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 238000002360 preparation method Methods 0.000 description 51
- 238000006243 chemical reaction Methods 0.000 description 50
- 239000007787 solid Substances 0.000 description 45
- 239000012044 organic layer Substances 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 40
- 230000015572 biosynthetic process Effects 0.000 description 38
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 36
- 238000003786 synthesis reaction Methods 0.000 description 36
- 102000005962 receptors Human genes 0.000 description 34
- 108020003175 receptors Proteins 0.000 description 34
- 239000011541 reaction mixture Substances 0.000 description 31
- 229910004298 SiO 2 Inorganic materials 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 239000000741 silica gel Substances 0.000 description 28
- 229910002027 silica gel Inorganic materials 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 27
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 27
- 239000010410 layer Substances 0.000 description 25
- 238000000746 purification Methods 0.000 description 24
- 238000010626 work up procedure Methods 0.000 description 24
- 239000002904 solvent Substances 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 21
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 239000003921 oil Substances 0.000 description 21
- 238000010992 reflux Methods 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 239000011734 sodium Substances 0.000 description 20
- 150000001299 aldehydes Chemical class 0.000 description 18
- 229910052786 argon Inorganic materials 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 125000004981 cycloalkylmethyl group Chemical group 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 239000007858 starting material Substances 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 239000003054 catalyst Substances 0.000 description 13
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 12
- 230000009467 reduction Effects 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 150000002460 imidazoles Chemical class 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 238000004296 chiral HPLC Methods 0.000 description 8
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 8
- 210000002683 foot Anatomy 0.000 description 8
- NBGMRMDAEWWFIR-UHFFFAOYSA-N imidazole-2-thione Chemical compound S=C1N=CC=N1 NBGMRMDAEWWFIR-UHFFFAOYSA-N 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 208000005298 acute pain Diseases 0.000 description 7
- 229910052681 coesite Inorganic materials 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 229910052906 cristobalite Inorganic materials 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 235000012239 silicon dioxide Nutrition 0.000 description 7
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 229910052682 stishovite Inorganic materials 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- 229910052905 tridymite Inorganic materials 0.000 description 7
- XVTQSYKCADSUHN-UHFFFAOYSA-N 3-methyl-2,3-dihydroinden-1-one Chemical compound C1=CC=C2C(C)CC(=O)C2=C1 XVTQSYKCADSUHN-UHFFFAOYSA-N 0.000 description 6
- DBOXRDYLMJMQBB-UHFFFAOYSA-N 6-methyl-indanone Natural products CC1=CC=C2CCC(=O)C2=C1 DBOXRDYLMJMQBB-UHFFFAOYSA-N 0.000 description 6
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 210000000548 hind-foot Anatomy 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000012266 salt solution Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 5
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 5
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 5
- 206010039897 Sedation Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 5
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 5
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 5
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 5
- 230000036280 sedation Effects 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- QWQBQRYFWNIDOC-UHFFFAOYSA-N (3,5-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC(F)=CC(F)=C1 QWQBQRYFWNIDOC-UHFFFAOYSA-N 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 4
- 229930182837 (R)-adrenaline Natural products 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 4
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 4
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 4
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 4
- ZQEXIXXJFSQPNA-UHFFFAOYSA-N 1h-imidazole-5-carbaldehyde Chemical compound O=CC1=CNC=N1 ZQEXIXXJFSQPNA-UHFFFAOYSA-N 0.000 description 4
- HVTLYEBHUKZJCL-UHFFFAOYSA-N 2-bromocyclopent-2-en-1-ol Chemical compound OC1CCC=C1Br HVTLYEBHUKZJCL-UHFFFAOYSA-N 0.000 description 4
- CHCCBPDEADMNCI-UHFFFAOYSA-N 3-Methyl-2-cyclopenten-1-one Chemical compound CC1=CC(=O)CC1 CHCCBPDEADMNCI-UHFFFAOYSA-N 0.000 description 4
- GCZQTQUHBZZQAC-UHFFFAOYSA-N 4,7-dimethyl-2,3-dihydroinden-1-one Chemical compound CC1=CC=C(C)C2=C1CCC2=O GCZQTQUHBZZQAC-UHFFFAOYSA-N 0.000 description 4
- RYLUBXDPWSHXME-UHFFFAOYSA-N 4-(2-phenylmethoxyethyl)cyclohexan-1-one Chemical compound C1CC(=O)CCC1CCOCC1=CC=CC=C1 RYLUBXDPWSHXME-UHFFFAOYSA-N 0.000 description 4
- IHKIFCYPXXKLKH-UHFFFAOYSA-N 4-(4-chloro-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C=2C(Cl)=CC=CC=2CC1C1=CNC(=S)N1 IHKIFCYPXXKLKH-UHFFFAOYSA-N 0.000 description 4
- VSQFZTUHCPQRHM-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroquinolin-6-ylmethyl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1CC2=CC=CN=C2CC1 VSQFZTUHCPQRHM-UHFFFAOYSA-N 0.000 description 4
- XPJSEXCZRWJJFN-UHFFFAOYSA-N 4-[[3-(hydroxymethyl)cyclohex-3-en-1-yl]methyl]-1,3-dihydroimidazol-2-one Chemical compound C1C(CO)=CCCC1CC1=CNC(=O)N1 XPJSEXCZRWJJFN-UHFFFAOYSA-N 0.000 description 4
- UVVYFYLSZIMKMC-UHFFFAOYSA-N 4-bromo-2,3-dihydroinden-1-one Chemical compound BrC1=CC=CC2=C1CCC2=O UVVYFYLSZIMKMC-UHFFFAOYSA-N 0.000 description 4
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 4
- RUORWXQKVXTQJJ-UHFFFAOYSA-N 4-methyl-2,3-dihydroinden-1-one Chemical compound CC1=CC=CC2=C1CCC2=O RUORWXQKVXTQJJ-UHFFFAOYSA-N 0.000 description 4
- WVPPBVAMKNQXJA-UHFFFAOYSA-N 5-fluoro-2,3-dihydroinden-1-one Chemical compound FC1=CC=C2C(=O)CCC2=C1 WVPPBVAMKNQXJA-UHFFFAOYSA-N 0.000 description 4
- KZFDXMQBHVRYHD-UHFFFAOYSA-N 8-chloro-2-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1C=2C(Cl)=CC=CC=2CCC1CC1=CNC(=S)N1 KZFDXMQBHVRYHD-UHFFFAOYSA-N 0.000 description 4
- 108060003345 Adrenergic Receptor Proteins 0.000 description 4
- 102000017910 Adrenergic receptor Human genes 0.000 description 4
- 229940126639 Compound 33 Drugs 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 241001061127 Thione Species 0.000 description 4
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 4
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 4
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229940127204 compound 29 Drugs 0.000 description 4
- 229940125877 compound 31 Drugs 0.000 description 4
- 238000001647 drug administration Methods 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 229960005139 epinephrine Drugs 0.000 description 4
- KYVVLBCWPRONOU-UHFFFAOYSA-N ethene hexane Chemical compound C=C.CCCCCC KYVVLBCWPRONOU-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000010907 mechanical stirring Methods 0.000 description 4
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- 210000001032 spinal nerve Anatomy 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 3
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 3
- NSOLDMJBEHWLCG-WLHGVMLRSA-N (E)-but-2-enedioic acid 5-[(3,4-dimethylcyclohex-3-en-1-yl)methyl]-1H-imidazole Chemical compound OC(=O)\C=C\C(O)=O.C1CC(C)=C(C)CC1CC1=CN=CN1 NSOLDMJBEHWLCG-WLHGVMLRSA-N 0.000 description 3
- SEHNFQNDEFTGRO-UHFFFAOYSA-N 2-(1h-imidazol-5-ylmethylidene)-3,4-dihydronaphthalen-1-one Chemical compound C1CC2=CC=CC=C2C(=O)C1=CC1=CNC=N1 SEHNFQNDEFTGRO-UHFFFAOYSA-N 0.000 description 3
- KJAHGBFQWVSPTH-UHFFFAOYSA-N 2-(2-bromocyclopent-2-en-1-yl)acetaldehyde Chemical compound BrC1=CCCC1CC=O KJAHGBFQWVSPTH-UHFFFAOYSA-N 0.000 description 3
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 3
- MXQAQVMJIDGQDO-UHFFFAOYSA-N 2-bromo-3-methylcyclopent-2-en-1-one Chemical compound CC1=C(Br)C(=O)CC1 MXQAQVMJIDGQDO-UHFFFAOYSA-N 0.000 description 3
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 3
- BWQWKFDNJMFHIO-UHFFFAOYSA-N 3-(1,2,3,4,5,6,7,8-octahydronaphthalen-2-ylmethyl)-1h-imidazole-2-thione Chemical compound S=C1NC=CN1CC1CC(CCCC2)=C2CC1 BWQWKFDNJMFHIO-UHFFFAOYSA-N 0.000 description 3
- UTCRAOWIAKBPSM-UHFFFAOYSA-N 4-(4,5,6,7-tetrahydro-1-benzothiophen-5-ylmethyl)-1,3-dihydroimidazol-2-one Chemical compound N1C(=O)NC=C1CC1CC(C=CS2)=C2CC1 UTCRAOWIAKBPSM-UHFFFAOYSA-N 0.000 description 3
- RXLIEGXEXQNYNN-UHFFFAOYSA-N 4-(4,5,6,7-tetrahydro-1-benzothiophen-5-ylmethyl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1CC(C=CS2)=C2CC1 RXLIEGXEXQNYNN-UHFFFAOYSA-N 0.000 description 3
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 3
- FWODAQUVVORWCN-JTQLQIEISA-N 4-[[(2s)-1,2,3,4-tetrahydronaphthalen-2-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1C[C@@H]1CC2=CC=CC=C2CC1 FWODAQUVVORWCN-JTQLQIEISA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- KSONICAHAPRCMV-UHFFFAOYSA-N 5-bromo-2,3-dihydroinden-1-one Chemical compound BrC1=CC=C2C(=O)CCC2=C1 KSONICAHAPRCMV-UHFFFAOYSA-N 0.000 description 3
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 3
- YHHBKPWMEXGLKE-UHFFFAOYSA-N 7,8-dihydro-6h-quinolin-5-one Chemical compound C1=CC=C2C(=O)CCCC2=N1 YHHBKPWMEXGLKE-UHFFFAOYSA-N 0.000 description 3
- NKVIZRKBYNZSAX-UHFFFAOYSA-N 7-iodo-2,3-dihydroinden-1-one Chemical compound IC1=CC=CC2=C1C(=O)CC2 NKVIZRKBYNZSAX-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- VUPGQWJGLPAGMZ-UHFFFAOYSA-N 8-chloro-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=C1C=CC=C2Cl VUPGQWJGLPAGMZ-UHFFFAOYSA-N 0.000 description 3
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 229930194542 Keto Natural products 0.000 description 3
- 238000000023 Kugelrohr distillation Methods 0.000 description 3
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- MNLVCBKWEVXHGE-UHFFFAOYSA-N [CH]1[CH]CC[CH]1 Chemical group [CH]1[CH]CC[CH]1 MNLVCBKWEVXHGE-UHFFFAOYSA-N 0.000 description 3
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125878 compound 36 Drugs 0.000 description 3
- 229940125807 compound 37 Drugs 0.000 description 3
- 229940127573 compound 38 Drugs 0.000 description 3
- 229940126540 compound 41 Drugs 0.000 description 3
- 229940127113 compound 57 Drugs 0.000 description 3
- 229940125900 compound 59 Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000010779 crude oil Substances 0.000 description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 3
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 3
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000002981 neuropathic effect Effects 0.000 description 3
- KOSYAAIZOGNATQ-UHFFFAOYSA-N o-phenyl chloromethanethioate Chemical compound ClC(=S)OC1=CC=CC=C1 KOSYAAIZOGNATQ-UHFFFAOYSA-N 0.000 description 3
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 3
- 239000011368 organic material Substances 0.000 description 3
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 229910000077 silane Inorganic materials 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 2
- AXUVBHSQWRRJSD-VIFPVBQESA-N (1s)-5-fluoro-2,3-dihydro-1h-indene-1-carboxylic acid Chemical compound FC1=CC=C2[C@@H](C(=O)O)CCC2=C1 AXUVBHSQWRRJSD-VIFPVBQESA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- CEBAHYWORUOILU-UHFFFAOYSA-N (4-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=C(C#N)C=C1 CEBAHYWORUOILU-UHFFFAOYSA-N 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- FAIBVLSPNAHVSQ-AATRIKPKSA-N (e)-3-(2,5-dimethylphenyl)prop-2-enoic acid Chemical compound CC1=CC=C(C)C(\C=C\C(O)=O)=C1 FAIBVLSPNAHVSQ-AATRIKPKSA-N 0.000 description 2
- KJRRTHHNKJBVBO-AATRIKPKSA-N (e)-3-(2-chlorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1Cl KJRRTHHNKJBVBO-AATRIKPKSA-N 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
- ZYZCALPXKGUGJI-DDVDASKDSA-M (e,3r,5s)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(F)C=CC=1N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C(C)C)N=C1C1=CC=CC=C1 ZYZCALPXKGUGJI-DDVDASKDSA-M 0.000 description 2
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 2
- OXFSTTJBVAAALW-UHFFFAOYSA-N 1,3-dihydroimidazole-2-thione Chemical compound SC1=NC=CN1 OXFSTTJBVAAALW-UHFFFAOYSA-N 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- SVYLWDRRTDLTGJ-UHFFFAOYSA-N 1-bromo-5-ethenoxycyclopentene Chemical compound BrC1=CCCC1OC=C SVYLWDRRTDLTGJ-UHFFFAOYSA-N 0.000 description 2
- SDJHPPZKZZWAKF-UHFFFAOYSA-N 2,3-dimethylbuta-1,3-diene Chemical compound CC(=C)C(C)=C SDJHPPZKZZWAKF-UHFFFAOYSA-N 0.000 description 2
- UZLQSPYGTUMKGS-UHFFFAOYSA-N 2,3-dimethylcyclopent-2-en-1-one Chemical compound CC1=C(C)C(=O)CC1 UZLQSPYGTUMKGS-UHFFFAOYSA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- XMQCVICRPBHGLO-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-2-yl)acetaldehyde Chemical compound C1=CC=C2CC(CC=O)CC2=C1 XMQCVICRPBHGLO-UHFFFAOYSA-N 0.000 description 2
- ADXRDJWVEZNATK-UHFFFAOYSA-N 2-(2-bromo-3-methylcyclopent-2-en-1-yl)acetaldehyde Chemical compound CC1=C(Br)C(CC=O)CC1 ADXRDJWVEZNATK-UHFFFAOYSA-N 0.000 description 2
- GNNWDIRIMUKYMA-UHFFFAOYSA-N 2-(2-bromocyclopent-2-en-1-yl)ethanol Chemical compound OCCC1CCC=C1Br GNNWDIRIMUKYMA-UHFFFAOYSA-N 0.000 description 2
- MPWWHZHNJMABFV-UHFFFAOYSA-N 2-(2-methylpropyl)cyclopent-2-en-1-ol Chemical compound CC(C)CC1=CCCC1O MPWWHZHNJMABFV-UHFFFAOYSA-N 0.000 description 2
- RUNIHLUEQQZRJV-UHFFFAOYSA-N 2-(2-phenylcyclopent-2-en-1-yl)acetaldehyde Chemical compound O=CCC1CCC=C1C1=CC=CC=C1 RUNIHLUEQQZRJV-UHFFFAOYSA-N 0.000 description 2
- KMCQYWNISNSLGD-UHFFFAOYSA-N 2-(3-ethyl-4-methylcyclohex-3-en-1-yl)acetaldehyde Chemical compound CCC1=C(C)CCC(CC=O)C1 KMCQYWNISNSLGD-UHFFFAOYSA-N 0.000 description 2
- FNCYDCAURLKZAD-UHFFFAOYSA-N 2-(3-methylcyclohex-3-en-1-yl)acetaldehyde Chemical compound CC1=CCCC(CC=O)C1 FNCYDCAURLKZAD-UHFFFAOYSA-N 0.000 description 2
- PTVUAUJRRSITIB-UHFFFAOYSA-N 2-(4,5-difluoro-2,3-dihydro-1h-inden-1-yl)ethanol Chemical compound C1=CC(F)=C(F)C2=C1C(CCO)CC2 PTVUAUJRRSITIB-UHFFFAOYSA-N 0.000 description 2
- HZEDWLLAMZSLKW-UHFFFAOYSA-N 2-(4-fluorophenyl)cyclopent-2-en-1-ol Chemical compound OC1CCC=C1C1=CC=C(F)C=C1 HZEDWLLAMZSLKW-UHFFFAOYSA-N 0.000 description 2
- ZGPMXOCCMUKZHZ-UHFFFAOYSA-N 2-(5-methyl-3,6-dihydro-2h-pyran-2-yl)acetaldehyde Chemical compound CC1=CCC(CC=O)OC1 ZGPMXOCCMUKZHZ-UHFFFAOYSA-N 0.000 description 2
- SWBATGDOKWSTLI-UHFFFAOYSA-N 2-(5-methyl-3,6-dihydro-2h-pyran-2-yl)ethanol Chemical compound CC1=CCC(CCO)OC1 SWBATGDOKWSTLI-UHFFFAOYSA-N 0.000 description 2
- YFXCFWKXFWIPIH-UHFFFAOYSA-N 2-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CC2=CC=CC=C2C(=O)C1CC1=CNC(=S)N1 YFXCFWKXFWIPIH-UHFFFAOYSA-N 0.000 description 2
- HUSGKZKQUTUMEN-UHFFFAOYSA-N 2-[2-(1h-imidazol-5-ylmethyl)-3,4-dihydro-2h-naphthalen-1-ylidene]acetonitrile Chemical compound C1CC2=CC=CC=C2C(=CC#N)C1CC1=CNC=N1 HUSGKZKQUTUMEN-UHFFFAOYSA-N 0.000 description 2
- JOYDZERVURZPOK-UHFFFAOYSA-N 2-[2-(2-fluorophenyl)cyclopent-2-en-1-yl]acetaldehyde Chemical compound FC1=CC=CC=C1C1=CCCC1CC=O JOYDZERVURZPOK-UHFFFAOYSA-N 0.000 description 2
- FUCZJRQHNKSIQH-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)-3-methylcyclopent-2-en-1-yl]acetaldehyde Chemical compound O=CCC1CCC(C)=C1C1=CC=C(F)C=C1 FUCZJRQHNKSIQH-UHFFFAOYSA-N 0.000 description 2
- WKIGKMSKGIUOHH-UHFFFAOYSA-N 2-[2-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]-3,4-dihydro-2h-naphthalen-1-ylidene]acetonitrile Chemical compound N1C(=S)NC=C1CC1C(=CC#N)C2=CC=CC=C2CC1 WKIGKMSKGIUOHH-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 2
- TZBRCDMGXKRTCN-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]-n,n-dimethylimidazole-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1C=CN=C1[Si](C)(C)C(C)(C)C TZBRCDMGXKRTCN-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- QEROMHXUKREOCB-UHFFFAOYSA-N 2-bromo-3-ethoxycyclopent-2-en-1-one Chemical compound CCOC1=C(Br)C(=O)CC1 QEROMHXUKREOCB-UHFFFAOYSA-N 0.000 description 2
- DCMUYMCATZCKMB-UHFFFAOYSA-N 2-cyclopent-3-en-1-ylacetonitrile Chemical compound N#CCC1CC=CC1 DCMUYMCATZCKMB-UHFFFAOYSA-N 0.000 description 2
- KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 2
- XJPPNIZKHLUVSD-UHFFFAOYSA-N 2-ethyl-1-methyl-4-(2-phenylmethoxyethyl)cyclohexan-1-ol Chemical compound C1CC(O)(C)C(CC)CC1CCOCC1=CC=CC=C1 XJPPNIZKHLUVSD-UHFFFAOYSA-N 0.000 description 2
- MWFMGBPGAXYFAR-UHFFFAOYSA-N 2-hydroxy-2-methylpropanenitrile Chemical compound CC(C)(O)C#N MWFMGBPGAXYFAR-UHFFFAOYSA-N 0.000 description 2
- YFYNHFVWTBQDGK-UHFFFAOYSA-N 3-(2,3-difluorophenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=CC(F)=C1F YFYNHFVWTBQDGK-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 2
- BWHDFCIPOXSDFK-UHFFFAOYSA-N 3-ethoxy-2-(4-fluorophenyl)cyclopent-2-en-1-one Chemical compound O=C1CCC(OCC)=C1C1=CC=C(F)C=C1 BWHDFCIPOXSDFK-UHFFFAOYSA-N 0.000 description 2
- XHAHAEVXYYITIQ-UHFFFAOYSA-N 3-ethylcyclopent-2-en-1-one Chemical compound CCC1=CC(=O)CC1 XHAHAEVXYYITIQ-UHFFFAOYSA-N 0.000 description 2
- FHKJIIXGCLYMCN-UHFFFAOYSA-N 4,5-difluoro-2,3-dihydroinden-1-one Chemical compound FC1=CC=C2C(=O)CCC2=C1F FHKJIIXGCLYMCN-UHFFFAOYSA-N 0.000 description 2
- URSBWPJARNQGBX-UHFFFAOYSA-N 4-(1,2,3,4,5,6-hexahydropentalen-1-ylmethyl)-1,3-dihydroimidazol-2-one Chemical compound N1C(=O)NC=C1CC1C(CCC2)=C2CC1 URSBWPJARNQGBX-UHFFFAOYSA-N 0.000 description 2
- KLFIAFIKVJLJTE-UHFFFAOYSA-N 4-(2,3-dihydro-1h-inden-2-ylmethyl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1CC2=CC=CC=C2C1 KLFIAFIKVJLJTE-UHFFFAOYSA-N 0.000 description 2
- CJJGDVPOPXDNRI-UHFFFAOYSA-N 4-(2-methyl-5-oxocyclopenten-1-yl)benzonitrile Chemical compound O=C1CCC(C)=C1C1=CC=C(C#N)C=C1 CJJGDVPOPXDNRI-UHFFFAOYSA-N 0.000 description 2
- RAODELPACAZXRR-UHFFFAOYSA-N 4-(5-bromo-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C2=CC(Br)=CC=C2CC1C1=CNC(=S)N1 RAODELPACAZXRR-UHFFFAOYSA-N 0.000 description 2
- NDXWQZOZWUPHBQ-UHFFFAOYSA-N 4-(5-fluoro-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C2=CC(F)=CC=C2CC1C1=CNC(=S)N1 NDXWQZOZWUPHBQ-UHFFFAOYSA-N 0.000 description 2
- KTWMAAYEVSRUTJ-UHFFFAOYSA-N 4-(cyclohex-2-en-1-ylmethyl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1C=CCCC1 KTWMAAYEVSRUTJ-UHFFFAOYSA-N 0.000 description 2
- FOOHYFUHXGIXNK-UHFFFAOYSA-N 4-(cyclopent-3-en-1-ylmethyl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1CC=CC1 FOOHYFUHXGIXNK-UHFFFAOYSA-N 0.000 description 2
- IYIZGWSLTYANAW-UHFFFAOYSA-N 4-[(1-oxo-3,4-dihydro-2h-naphthalen-2-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C1CC2=CC=CC=C2C(=O)C1CC1=CNC(=O)N1 IYIZGWSLTYANAW-UHFFFAOYSA-N 0.000 description 2
- DTTXUTPZPKDGJH-UHFFFAOYSA-N 4-[(3,4-dimethylcyclohex-3-en-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C1CC(C)=C(C)CC1CC1=CNC(=O)N1 DTTXUTPZPKDGJH-UHFFFAOYSA-N 0.000 description 2
- VDPIYIAVBAQISZ-UHFFFAOYSA-N 4-[(3-ethyl-4-methylcyclohex-3-en-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C1C(CC)=C(C)CCC1CC1=CNC(=O)N1 VDPIYIAVBAQISZ-UHFFFAOYSA-N 0.000 description 2
- LLPDVTOKFQTYHL-UHFFFAOYSA-N 4-[(3-ethyl-4-methylcyclohex-3-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1C(CC)=C(C)CCC1CC1=CNC(=S)N1 LLPDVTOKFQTYHL-UHFFFAOYSA-N 0.000 description 2
- ZRWPFXDIUAUQDW-UHFFFAOYSA-N 4-[(3-ethylcyclohex-3-en-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C1C(CC)=CCCC1CC1=CNC(=O)N1 ZRWPFXDIUAUQDW-UHFFFAOYSA-N 0.000 description 2
- VDPBXWLJWOWLSW-UHFFFAOYSA-N 4-[(3-methylcyclohex-3-en-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C1C(C)=CCCC1CC1=CNC(=O)N1 VDPBXWLJWOWLSW-UHFFFAOYSA-N 0.000 description 2
- YREREDNJWAMKAR-UHFFFAOYSA-N 4-[(4,5-difluoro-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC2=C(F)C(F)=CC=C2C1CC1=CNC(=S)N1 YREREDNJWAMKAR-UHFFFAOYSA-N 0.000 description 2
- MITXGNOZXRGPRD-UHFFFAOYSA-N 4-[(4-methylcyclohex-3-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC(C)=CCC1CC1=CNC(=S)N1 MITXGNOZXRGPRD-UHFFFAOYSA-N 0.000 description 2
- PCBXUTPYXKBFHV-UHFFFAOYSA-N 4-[(5-hydroxy-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C1CC2=CC(O)=CC=C2C1CC1=CNC(=O)N1 PCBXUTPYXKBFHV-UHFFFAOYSA-N 0.000 description 2
- UFUOGALEIPSDPK-SECBINFHSA-N 4-[[(1r)-5-fluoro-2,3-dihydro-1h-inden-1-yl]methyl]-1,3-dihydroimidazol-2-one Chemical compound C([C@@H]1C2=CC=C(C=C2CC1)F)C1=CNC(=O)N1 UFUOGALEIPSDPK-SECBINFHSA-N 0.000 description 2
- YPNRLQHEOGIBQZ-UHFFFAOYSA-N 4-[[2-(2-methylpropyl)cyclopent-2-en-1-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound CC(C)CC1=CCCC1CC1=CNC(=S)N1 YPNRLQHEOGIBQZ-UHFFFAOYSA-N 0.000 description 2
- MYCZDIIPHIGLCH-UHFFFAOYSA-N 4-chloro-2,3-dihydroinden-1-one Chemical compound ClC1=CC=CC2=C1CCC2=O MYCZDIIPHIGLCH-UHFFFAOYSA-N 0.000 description 2
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- QRUZVGOFWDUHMX-UHFFFAOYSA-N 4-phenylimidazole-2-thione Chemical class S=C1N=CC(C=2C=CC=CC=2)=N1 QRUZVGOFWDUHMX-UHFFFAOYSA-N 0.000 description 2
- XWZGNWCKXLECBO-UHFFFAOYSA-N 5,7-difluoro-2,3-dihydroinden-1-one Chemical compound FC1=CC(F)=CC2=C1C(=O)CC2 XWZGNWCKXLECBO-UHFFFAOYSA-N 0.000 description 2
- VAHSJJMGJLMZFO-UHFFFAOYSA-N 5-(oxan-2-yloxy)-2,3-dihydroinden-1-one Chemical compound C=1C=C2C(=O)CCC2=CC=1OC1CCCCO1 VAHSJJMGJLMZFO-UHFFFAOYSA-N 0.000 description 2
- FXFHMVHYSHJDJN-UHFFFAOYSA-N 5-[(3-ethenylcyclohex-3-en-1-yl)methyl]-1h-imidazole Chemical compound C1C(C=C)=CCCC1CC1=CNC=N1 FXFHMVHYSHJDJN-UHFFFAOYSA-N 0.000 description 2
- PPKMRSFNZHHNRY-UHFFFAOYSA-N 5-[2-tri(propan-2-yl)silyloxyethyl]cyclohexene-1-carbaldehyde Chemical compound CC(C)[Si](C(C)C)(C(C)C)OCCC1CCC=C(C=O)C1 PPKMRSFNZHHNRY-UHFFFAOYSA-N 0.000 description 2
- OMJPTHPPEYUYLP-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1h-indene-2-carboxylic acid Chemical compound C1=C(Br)C=C2CC(C(=O)O)CC2=C1 OMJPTHPPEYUYLP-UHFFFAOYSA-N 0.000 description 2
- MEDSHTHCZIOVPU-UHFFFAOYSA-N 5-chloro-2,3-dihydroinden-1-one Chemical compound ClC1=CC=C2C(=O)CCC2=C1 MEDSHTHCZIOVPU-UHFFFAOYSA-N 0.000 description 2
- QOPRWBRNMPANKN-UHFFFAOYSA-N 5-methoxy-2,3-dihydroinden-1-one Chemical compound COC1=CC=C2C(=O)CCC2=C1 QOPRWBRNMPANKN-UHFFFAOYSA-N 0.000 description 2
- UKDWMOMUOSRZSU-UHFFFAOYSA-N 6,7-dichloro-2,3-dihydroinden-1-one Chemical compound ClC1=CC=C2CCC(=O)C2=C1Cl UKDWMOMUOSRZSU-UHFFFAOYSA-N 0.000 description 2
- GJEKNELSXNSYAQ-UHFFFAOYSA-N 6,7-dihydro-5h-1-benzothiophen-4-one Chemical compound O=C1CCCC2=C1C=CS2 GJEKNELSXNSYAQ-UHFFFAOYSA-N 0.000 description 2
- LMZRFCHKEGSPIJ-UHFFFAOYSA-N 6-(1h-imidazol-5-ylmethyl)-7,8-dihydro-6h-quinolin-5-one Chemical compound C1CC2=NC=CC=C2C(=O)C1CC1=CNC=N1 LMZRFCHKEGSPIJ-UHFFFAOYSA-N 0.000 description 2
- YZVNTBGRVBMHBL-UHFFFAOYSA-N 6-chloro-7-methyl-2,3-dihydroinden-1-one Chemical compound C1=C(Cl)C(C)=C2C(=O)CCC2=C1 YZVNTBGRVBMHBL-UHFFFAOYSA-N 0.000 description 2
- UJGDLLGKMWVCPT-UHFFFAOYSA-N 6-methoxy-2,3-dihydroinden-1-one Chemical compound COC1=CC=C2CCC(=O)C2=C1 UJGDLLGKMWVCPT-UHFFFAOYSA-N 0.000 description 2
- GZRHFGSCUQBJHR-UHFFFAOYSA-N 7-amino-2,3-dihydroinden-1-one Chemical compound NC1=CC=CC2=C1C(=O)CC2 GZRHFGSCUQBJHR-UHFFFAOYSA-N 0.000 description 2
- LCDBVCWOKHNEMZ-UHFFFAOYSA-N 8-(2-phenylmethoxyethyl)-1,4-dioxaspiro[4.5]decane Chemical compound C=1C=CC=CC=1COCCC(CC1)CCC21OCCO2 LCDBVCWOKHNEMZ-UHFFFAOYSA-N 0.000 description 2
- QJPASCYMKASYSC-UHFFFAOYSA-N 8-(hydroxymethyl)-2-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1C=2C(CO)=CC=CC=2CCC1CC1=CNC(=S)N1 QJPASCYMKASYSC-UHFFFAOYSA-N 0.000 description 2
- CLMVCPDNWWFIDG-UHFFFAOYSA-N 8-(oxan-2-yloxymethyl)-3,4-dihydro-2h-naphthalen-1-one Chemical compound C=12C(=O)CCCC2=CC=CC=1COC1CCCCO1 CLMVCPDNWWFIDG-UHFFFAOYSA-N 0.000 description 2
- FOFIZBDOYSOLKU-UHFFFAOYSA-N 8-amino-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=C1C=CC=C2N FOFIZBDOYSOLKU-UHFFFAOYSA-N 0.000 description 2
- RYMWBQHSBRCBQV-UHFFFAOYSA-N 8-fluoro-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=C1C=CC=C2F RYMWBQHSBRCBQV-UHFFFAOYSA-N 0.000 description 2
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 2
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 2
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 2
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 description 2
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 108091006068 Gq proteins Proteins 0.000 description 2
- 102000052606 Gq-G11 GTP-Binding Protein alpha Subunits Human genes 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- 101100189356 Mus musculus Papolb gene Proteins 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 2
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229940126545 compound 53 Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- ZBQUMMFUJLOTQC-UHFFFAOYSA-N dichloronickel;3-diphenylphosphaniumylpropyl(diphenyl)phosphanium Chemical compound Cl[Ni]Cl.C=1C=CC=CC=1[PH+](C=1C=CC=CC=1)CCC[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 ZBQUMMFUJLOTQC-UHFFFAOYSA-N 0.000 description 2
- BUMGIEFFCMBQDG-UHFFFAOYSA-N dichlorosilicon Chemical compound Cl[Si]Cl BUMGIEFFCMBQDG-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- JTNJTEUXMSYSSP-FPLPWBNLSA-N ethyl (2z)-2-(4,5-difluoro-2,3-dihydroinden-1-ylidene)acetate Chemical compound C1=CC(F)=C(F)C2=C1C(=C/C(=O)OCC)\CC2 JTNJTEUXMSYSSP-FPLPWBNLSA-N 0.000 description 2
- SDJWACIISYQUDN-LUAWRHEFSA-N ethyl (2z)-2-(6,7-dihydro-5h-quinolin-8-ylidene)acetate Chemical compound C1=CN=C2C(=C/C(=O)OCC)\CCCC2=C1 SDJWACIISYQUDN-LUAWRHEFSA-N 0.000 description 2
- GIVQRYJCGQQDCE-UHFFFAOYSA-N ethyl 2-(4-chloro-2,3-dihydro-1h-inden-1-yl)acetate Chemical compound C1=CC=C(Cl)C2=C1C(CC(=O)OCC)CC2 GIVQRYJCGQQDCE-UHFFFAOYSA-N 0.000 description 2
- SRWQONDOPOMPFZ-UHFFFAOYSA-N ethyl 2-(5,6,7,8-tetrahydroquinolin-8-yl)acetate Chemical compound C1=CN=C2C(CC(=O)OCC)CCCC2=C1 SRWQONDOPOMPFZ-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 2
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- XTUYFDKBTCSVKE-UHFFFAOYSA-N methyl 2-oxo-5-(2-phenylmethoxyethyl)cyclohexane-1-carboxylate Chemical compound C1CC(=O)C(C(=O)OC)CC1CCOCC1=CC=CC=C1 XTUYFDKBTCSVKE-UHFFFAOYSA-N 0.000 description 2
- MPIBLYONMGATOH-UHFFFAOYSA-N methyl 4-chloro-2,3-dihydro-1h-indene-2-carboxylate Chemical compound C1=CC(Cl)=C2CC(C(=O)OC)CC2=C1 MPIBLYONMGATOH-UHFFFAOYSA-N 0.000 description 2
- MWLVXTHSYXJETB-UHFFFAOYSA-N methyl 5-(2-phenylmethoxyethyl)cyclohexene-1-carboxylate Chemical compound C1C(C(=O)OC)=CCCC1CCOCC1=CC=CC=C1 MWLVXTHSYXJETB-UHFFFAOYSA-N 0.000 description 2
- JAPHEQMSWZSACK-UHFFFAOYSA-N methyl 5-bromo-2,3-dihydro-1h-indene-2-carboxylate Chemical compound C1=C(Br)C=C2CC(C(=O)OC)CC2=C1 JAPHEQMSWZSACK-UHFFFAOYSA-N 0.000 description 2
- MIZJGPQVOBOFOU-UHFFFAOYSA-N methyl 5-fluoro-2,3-dihydro-1h-indene-2-carboxylate Chemical compound C1=C(F)C=C2CC(C(=O)OC)CC2=C1 MIZJGPQVOBOFOU-UHFFFAOYSA-N 0.000 description 2
- HJYFQVWOJMRKDU-UHFFFAOYSA-N methyl 6-bromo-3-oxo-1,2-dihydroindene-2-carboxylate Chemical compound BrC1=CC=C2C(=O)C(C(=O)OC)CC2=C1 HJYFQVWOJMRKDU-UHFFFAOYSA-N 0.000 description 2
- OBWFJXLKRAFEDI-UHFFFAOYSA-N methyl cyanoformate Chemical compound COC(=O)C#N OBWFJXLKRAFEDI-UHFFFAOYSA-N 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- LHJCZOXMCGQVDQ-UHFFFAOYSA-N tri(propan-2-yl)silyl trifluoromethanesulfonate Chemical compound CC(C)[Si](C(C)C)(C(C)C)OS(=O)(=O)C(F)(F)F LHJCZOXMCGQVDQ-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 2
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AXUVBHSQWRRJSD-SECBINFHSA-N (1r)-5-fluoro-2,3-dihydro-1h-indene-1-carboxylic acid Chemical compound FC1=CC=C2[C@H](C(=O)O)CCC2=C1 AXUVBHSQWRRJSD-SECBINFHSA-N 0.000 description 1
- HVTLYEBHUKZJCL-YFKPBYRVSA-N (1s)-2-bromocyclopent-2-en-1-ol Chemical compound O[C@H]1CCC=C1Br HVTLYEBHUKZJCL-YFKPBYRVSA-N 0.000 description 1
- KTOJGSDLJNUAEP-UHFFFAOYSA-N (2,5-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC(F)=CC=C1F KTOJGSDLJNUAEP-UHFFFAOYSA-N 0.000 description 1
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- RMGYQBHKEWWTOY-UHFFFAOYSA-N (3,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(F)=C1 RMGYQBHKEWWTOY-UHFFFAOYSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- JFCLNCVCDFUJPO-UHFFFAOYSA-N (5-chlorothiophen-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)S1 JFCLNCVCDFUJPO-UHFFFAOYSA-N 0.000 description 1
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- LNPYEJPTPDQXNO-ONEGZZNKSA-N (e)-2-(1h-imidazol-2-yl)but-2-enedioic acid Chemical class OC(=O)\C=C(\C(O)=O)C1=NC=CN1 LNPYEJPTPDQXNO-ONEGZZNKSA-N 0.000 description 1
- NVQHKPLMLCHFSU-SNAWJCMRSA-N (e)-3-(2,3-difluorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(F)=C1F NVQHKPLMLCHFSU-SNAWJCMRSA-N 0.000 description 1
- IOUDZAFBPDDAMK-AATRIKPKSA-N (e)-3-(2-fluorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1F IOUDZAFBPDDAMK-AATRIKPKSA-N 0.000 description 1
- HXBOHZQZTWAEHJ-DUXPYHPUSA-N (e)-3-(3,4-difluorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(F)C(F)=C1 HXBOHZQZTWAEHJ-DUXPYHPUSA-N 0.000 description 1
- MBAWRXICVNIUGY-OWOJBTEDSA-N (e)-3-(3,5-difluorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC(F)=CC(F)=C1 MBAWRXICVNIUGY-OWOJBTEDSA-N 0.000 description 1
- WIKBZUXHNPONPP-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoro-2-iodo-2-(trifluoromethyl)propane Chemical compound FC(F)(F)C(I)(C(F)(F)F)C(F)(F)F WIKBZUXHNPONPP-UHFFFAOYSA-N 0.000 description 1
- JAAJQSRLGAYGKZ-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-ol Chemical compound C1=CC=C2C(O)CCCC2=C1 JAAJQSRLGAYGKZ-UHFFFAOYSA-N 0.000 description 1
- NTAGXJQHJQUOOA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalene-2-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)CCC2=C1 NTAGXJQHJQUOOA-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- VKRKCBWIVLSRBJ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC21OCCO2 VKRKCBWIVLSRBJ-UHFFFAOYSA-N 0.000 description 1
- VKGOZWQNMQSNNR-UHFFFAOYSA-N 1-(1h-imidazol-5-ylmethyl)-2,3-dihydro-1h-inden-5-ol Chemical compound C1CC2=CC(O)=CC=C2C1CC1=CNC=N1 VKGOZWQNMQSNNR-UHFFFAOYSA-N 0.000 description 1
- QHDHNVFIKWGRJR-UHFFFAOYSA-N 1-cyclohexenol Chemical compound OC1=CCCCC1 QHDHNVFIKWGRJR-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- VKMPHJINXYTSIM-UHFFFAOYSA-N 2,3,4,5,6,7-hexahydroinden-1-one Chemical compound C1CCCC2=C1C(=O)CC2 VKMPHJINXYTSIM-UHFFFAOYSA-N 0.000 description 1
- QAOJBHRZQQDFHA-UHFFFAOYSA-N 2,3-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1Cl QAOJBHRZQQDFHA-UHFFFAOYSA-N 0.000 description 1
- RXTJLDXSGNEJIT-UHFFFAOYSA-N 2,3-dihydro-1h-inden-4-amine Chemical compound NC1=CC=CC2=C1CCC2 RXTJLDXSGNEJIT-UHFFFAOYSA-N 0.000 description 1
- XUDCMQBOWOLYCF-UHFFFAOYSA-N 2,3-dihydro-1h-indene-2-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)CC2=C1 XUDCMQBOWOLYCF-UHFFFAOYSA-N 0.000 description 1
- CVQSWZMJOGOPAV-UHFFFAOYSA-N 2,3-dihydrothiochromen-4-one Chemical compound C1=CC=C2C(=O)CCSC2=C1 CVQSWZMJOGOPAV-UHFFFAOYSA-N 0.000 description 1
- GQNBYFSDTYPZNS-UHFFFAOYSA-N 2-(1h-imidazol-5-ylmethyl)-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CC2=CC=CC=C2C(=O)C1CC1=CNC=N1 GQNBYFSDTYPZNS-UHFFFAOYSA-N 0.000 description 1
- TULDPXYHBFBRGW-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-2-yl)acetic acid Chemical compound C1=CC=C2CC(CC(=O)O)CC2=C1 TULDPXYHBFBRGW-UHFFFAOYSA-N 0.000 description 1
- SSJGMHHEVDFMJM-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-2-yl)ethanol Chemical compound C1=CC=C2CC(CCO)CC2=C1 SSJGMHHEVDFMJM-UHFFFAOYSA-N 0.000 description 1
- PKNBDORLQMDGFS-UHFFFAOYSA-N 2-(2,5-difluorophenyl)cyclopent-2-en-1-ol Chemical compound OC1CCC=C1C1=CC(F)=CC=C1F PKNBDORLQMDGFS-UHFFFAOYSA-N 0.000 description 1
- QPRRVENIBBPMLY-UHFFFAOYSA-N 2-(3-ethyl-4-methylcyclohex-3-en-1-yl)ethoxymethylbenzene Chemical compound C1C(CC)=C(C)CCC1CCOCC1=CC=CC=C1 QPRRVENIBBPMLY-UHFFFAOYSA-N 0.000 description 1
- OLCXLOSLEXEPED-UHFFFAOYSA-N 2-(3-ethynylcyclohex-3-en-1-yl)ethanol Chemical compound OCCC1CCC=C(C#C)C1 OLCXLOSLEXEPED-UHFFFAOYSA-N 0.000 description 1
- GODICVOREPEYAD-UHFFFAOYSA-N 2-(3-ethynylcyclohex-3-en-1-yl)ethoxy-tri(propan-2-yl)silane Chemical compound CC(C)[Si](C(C)C)(C(C)C)OCCC1CCC=C(C#C)C1 GODICVOREPEYAD-UHFFFAOYSA-N 0.000 description 1
- GBCFJGPDSLVMSK-UHFFFAOYSA-N 2-(3-methylcyclohex-3-en-1-yl)ethoxymethylbenzene Chemical compound C1C(C)=CCCC1CCOCC1=CC=CC=C1 GBCFJGPDSLVMSK-UHFFFAOYSA-N 0.000 description 1
- JZGLECLGVQRPPI-NSHDSACASA-N 2-(4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-[4-(trifluoromethoxy)phenyl]ethyl]acetamide Chemical compound O=C1C2=C(N=NN1CC(=O)N[C@@H](C)C1=CC=C(C=C1)OC(F)(F)F)C=CC=C2 JZGLECLGVQRPPI-NSHDSACASA-N 0.000 description 1
- DAXUSGJACKGZOZ-UHFFFAOYSA-N 2-[(1-tritylimidazol-4-yl)methyl]-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CC2=CC=CC=C2C(=O)C1CC(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 DAXUSGJACKGZOZ-UHFFFAOYSA-N 0.000 description 1
- UHQFOJYYAJKFCQ-UHFFFAOYSA-N 2-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]-2,3-dihydroinden-1-one Chemical compound C1C2=CC=CC=C2C(=O)C1CC1=CNC(=S)N1 UHQFOJYYAJKFCQ-UHFFFAOYSA-N 0.000 description 1
- XKHBQMNIQXMAGN-UHFFFAOYSA-N 2-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]-3,4,5,6,7,8-hexahydro-2h-naphthalen-1-one Chemical compound C1CC(CCCC2)=C2C(=O)C1CC1=CNC(=S)N1 XKHBQMNIQXMAGN-UHFFFAOYSA-N 0.000 description 1
- BWZNHXQDYFLSQD-UHFFFAOYSA-N 2-[2-(2-fluorophenyl)cyclopent-2-en-1-yl]ethanol Chemical compound OCCC1CCC=C1C1=CC=CC=C1F BWZNHXQDYFLSQD-UHFFFAOYSA-N 0.000 description 1
- VLRPLRCWELKRDW-UHFFFAOYSA-N 2-[2-[(1-tritylimidazol-4-yl)methyl]-3,4-dihydro-2h-naphthalen-1-ylidene]acetonitrile Chemical compound C1CC2=CC=CC=C2C(=CC#N)C1CC(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 VLRPLRCWELKRDW-UHFFFAOYSA-N 0.000 description 1
- FAKDFNUWBOPPEG-UHFFFAOYSA-N 2-[3-(2-tert-butylsilyloxypropan-2-yl)cyclohex-3-en-1-yl]acetaldehyde Chemical compound C(C)(C)(C)[SiH2]OC(C=1CC(CCC=1)CC=O)(C)C FAKDFNUWBOPPEG-UHFFFAOYSA-N 0.000 description 1
- KPGNMJBFDNVJRC-UHFFFAOYSA-N 2-[3-(2-tert-butylsilyloxypropan-2-yl)cyclohex-3-en-1-yl]ethanol Chemical compound C(C)(C)(C)[SiH2]OC(C=1CC(CCC1)CCO)(C)C KPGNMJBFDNVJRC-UHFFFAOYSA-N 0.000 description 1
- LWYUFCUTIFHVQS-UHFFFAOYSA-N 2-bromo-3-methylcyclopent-2-en-1-ol Chemical compound CC1=C(Br)C(O)CC1 LWYUFCUTIFHVQS-UHFFFAOYSA-N 0.000 description 1
- WJZDXONSAPNKGB-UHFFFAOYSA-N 2-bromocyclopent-2-en-1-one Chemical compound BrC1=CCCC1=O WJZDXONSAPNKGB-UHFFFAOYSA-N 0.000 description 1
- UKNVQOLBSXPAEC-UHFFFAOYSA-N 2-chlorocyclopent-2-en-1-one Chemical compound ClC1=CCCC1=O UKNVQOLBSXPAEC-UHFFFAOYSA-N 0.000 description 1
- SGGYCQUJVSDNFD-UHFFFAOYSA-N 2-ethenylcyclopent-2-en-1-ol Chemical compound OC1CCC=C1C=C SGGYCQUJVSDNFD-UHFFFAOYSA-N 0.000 description 1
- VZNWOMPJMFNVHV-UHFFFAOYSA-N 2-ethyl-3-methylcyclopent-2-en-1-ol Chemical compound CCC1=C(C)CCC1O VZNWOMPJMFNVHV-UHFFFAOYSA-N 0.000 description 1
- CFBHNGIIYJAJSD-UHFFFAOYSA-N 2-ethyl-4-(2-phenylmethoxyethyl)cyclohexan-1-one Chemical compound C1CC(=O)C(CC)CC1CCOCC1=CC=CC=C1 CFBHNGIIYJAJSD-UHFFFAOYSA-N 0.000 description 1
- AHAATKOSNXIXCX-UHFFFAOYSA-N 2-ethylcyclohex-2-en-1-one Chemical compound CCC1=CCCCC1=O AHAATKOSNXIXCX-UHFFFAOYSA-N 0.000 description 1
- GKDBCXCOTZXACW-UHFFFAOYSA-N 2-ethylcyclopent-2-en-1-one Chemical compound CCC1=CCCC1=O GKDBCXCOTZXACW-UHFFFAOYSA-N 0.000 description 1
- BEKNOGMQVKBMQN-UHFFFAOYSA-N 2-methyl-2,3-dihydroinden-1-one Chemical compound C1=CC=C2C(=O)C(C)CC2=C1 BEKNOGMQVKBMQN-UHFFFAOYSA-N 0.000 description 1
- LKTNAAYQZJAXCJ-UHFFFAOYSA-N 2-methylcyclohex-2-en-1-one Chemical compound CC1=CCCCC1=O LKTNAAYQZJAXCJ-UHFFFAOYSA-N 0.000 description 1
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
- OTTJAHSRCKAEPE-UHFFFAOYSA-N 2-prop-1-enylcyclopent-2-en-1-ol Chemical compound CC=CC1=CCCC1O OTTJAHSRCKAEPE-UHFFFAOYSA-N 0.000 description 1
- RCMSABHBOBOMFR-UHFFFAOYSA-N 3,4,5,6-tetrahydro-2h-pentalen-1-one Chemical compound C1CCC2=C1C(=O)CC2 RCMSABHBOBOMFR-UHFFFAOYSA-N 0.000 description 1
- AOACQJFIGWNQBC-UHFFFAOYSA-N 3-(2-bromophenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1Br AOACQJFIGWNQBC-UHFFFAOYSA-N 0.000 description 1
- IMYBFKQCTCBNPY-UHFFFAOYSA-N 3-(3-fluoro-5-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC(F)=CC(C=CC(O)=O)=C1 IMYBFKQCTCBNPY-UHFFFAOYSA-N 0.000 description 1
- HXGHMCLCSPQMOR-UHFFFAOYSA-N 3-chloro-2-methylbenzoic acid Chemical compound CC1=C(Cl)C=CC=C1C(O)=O HXGHMCLCSPQMOR-UHFFFAOYSA-N 0.000 description 1
- JWCFJPLIRVYENQ-UHFFFAOYSA-N 3-ethoxycyclohex-2-en-1-one Chemical compound CCOC1=CC(=O)CCC1 JWCFJPLIRVYENQ-UHFFFAOYSA-N 0.000 description 1
- SUQNVCCJLBQVEI-UHFFFAOYSA-N 3-ethoxycyclopent-2-en-1-one Chemical compound CCOC1=CC(=O)CC1 SUQNVCCJLBQVEI-UHFFFAOYSA-N 0.000 description 1
- GXAAHOMAKUINBR-UHFFFAOYSA-N 3-ethyl-2-(4-fluorophenyl)cyclopent-2-en-1-ol Chemical compound OC1CCC(CC)=C1C1=CC=C(F)C=C1 GXAAHOMAKUINBR-UHFFFAOYSA-N 0.000 description 1
- ZNRGSYUVFVNSAW-UHFFFAOYSA-N 3-nitrophenylboronic acid Chemical compound OB(O)C1=CC=CC([N+]([O-])=O)=C1 ZNRGSYUVFVNSAW-UHFFFAOYSA-N 0.000 description 1
- UXEQLEPZWLBJDU-UHFFFAOYSA-N 4-(1,2,3,4,5,6,7,8-octahydronaphthalen-1-ylmethyl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1C(CCCC2)=C2CCC1 UXEQLEPZWLBJDU-UHFFFAOYSA-N 0.000 description 1
- LXRVODJEONQBGT-UHFFFAOYSA-N 4-(1,2,3,4,5,6-hexahydropentalen-1-ylmethyl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1C(CCC2)=C2CC1 LXRVODJEONQBGT-UHFFFAOYSA-N 0.000 description 1
- MFGMQZAMMNYQGJ-UHFFFAOYSA-N 4-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-1,3-dihydroimidazol-2-one Chemical compound N1C(=O)NC=C1CC1C2=CC=CC=C2CCC1 MFGMQZAMMNYQGJ-UHFFFAOYSA-N 0.000 description 1
- KZKOOHLABLQDNS-UHFFFAOYSA-N 4-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1C2=CC=CC=C2CCC1 KZKOOHLABLQDNS-UHFFFAOYSA-N 0.000 description 1
- JKUWVPUCESBECF-UHFFFAOYSA-N 4-(1,2,3,4-tetrahydronaphthalen-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1C1CC2=CC=CC=C2CC1 JKUWVPUCESBECF-UHFFFAOYSA-N 0.000 description 1
- FWODAQUVVORWCN-UHFFFAOYSA-N 4-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1CC2=CC=CC=C2CC1 FWODAQUVVORWCN-UHFFFAOYSA-N 0.000 description 1
- VRZWYPNQEVOAGP-UHFFFAOYSA-N 4-(1-methyl-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C2=CC=CC=C2C(C)C1C1=CNC(=S)N1 VRZWYPNQEVOAGP-UHFFFAOYSA-N 0.000 description 1
- GTSGENCQCKRYKE-UHFFFAOYSA-N 4-(2,3,4,5,6,7-hexahydro-1h-inden-1-ylmethyl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1C(CCCC2)=C2CC1 GTSGENCQCKRYKE-UHFFFAOYSA-N 0.000 description 1
- CAFMQWRCFOTIFB-UHFFFAOYSA-N 4-(2,3-dihydro-1h-inden-1-ylmethyl)-1,3-dihydroimidazol-2-one Chemical compound N1C(=O)NC=C1CC1C2=CC=CC=C2CC1 CAFMQWRCFOTIFB-UHFFFAOYSA-N 0.000 description 1
- IGEQJXDJMYMIFJ-UHFFFAOYSA-N 4-(2,3-dihydro-1h-inden-1-ylmethyl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1C2=CC=CC=C2CC1 IGEQJXDJMYMIFJ-UHFFFAOYSA-N 0.000 description 1
- HUJDEXUKGMPSDB-UHFFFAOYSA-N 4-(2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1C1CC2=CC=CC=C2C1 HUJDEXUKGMPSDB-UHFFFAOYSA-N 0.000 description 1
- BCEXHABGXALHQU-UHFFFAOYSA-N 4-(2-hydroxyethyl)cyclohexan-1-one Chemical compound OCCC1CCC(=O)CC1 BCEXHABGXALHQU-UHFFFAOYSA-N 0.000 description 1
- KBNLZGPTHHBEHS-UHFFFAOYSA-N 4-(3,4-dihydro-2h-thiochromen-4-ylmethyl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1C2=CC=CC=C2SCC1 KBNLZGPTHHBEHS-UHFFFAOYSA-N 0.000 description 1
- QEDLQGBIIFDNGH-UHFFFAOYSA-N 4-(4,5-dichloro-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C2=C(Cl)C(Cl)=CC=C2CC1C1=CNC(=S)N1 QEDLQGBIIFDNGH-UHFFFAOYSA-N 0.000 description 1
- HBPLMICDDCCOKZ-UHFFFAOYSA-N 4-(4,6-difluoro-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C=2C(F)=CC(F)=CC=2CC1C1=CNC(=S)N1 HBPLMICDDCCOKZ-UHFFFAOYSA-N 0.000 description 1
- IAZZETFOWVZKQM-UHFFFAOYSA-N 4-(4,7-dimethyl-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C=2C(C)=CC=C(C)C=2CC1C1=CNC(=S)N1 IAZZETFOWVZKQM-UHFFFAOYSA-N 0.000 description 1
- FYGOWGHPUUAMLO-UHFFFAOYSA-N 4-(4-bromo-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C=2C(Br)=CC=CC=2CC1C1=CNC(=S)N1 FYGOWGHPUUAMLO-UHFFFAOYSA-N 0.000 description 1
- YZFXBMKRNNFNBK-UHFFFAOYSA-N 4-(4-fluoro-6-methoxy-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C=2C(F)=CC(OC)=CC=2CC1C1=CNC(=S)N1 YZFXBMKRNNFNBK-UHFFFAOYSA-N 0.000 description 1
- NMPHIYLWRBOANZ-UHFFFAOYSA-N 4-(4-iodo-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C=2C(I)=CC=CC=2CC1C1=CNC(=S)N1 NMPHIYLWRBOANZ-UHFFFAOYSA-N 0.000 description 1
- PMLQJLIPYKUEGK-UHFFFAOYSA-N 4-(4-methyl-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C=2C(C)=CC=CC=2CC1C1=CNC(=S)N1 PMLQJLIPYKUEGK-UHFFFAOYSA-N 0.000 description 1
- QAQKUOALLCXJAG-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroquinolin-8-ylmethyl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1C2=NC=CC=C2CCC1 QAQKUOALLCXJAG-UHFFFAOYSA-N 0.000 description 1
- UAATTWCMCMWAPW-UHFFFAOYSA-N 4-(5-chloro-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C2=CC(Cl)=CC=C2CC1C1=CNC(=S)N1 UAATTWCMCMWAPW-UHFFFAOYSA-N 0.000 description 1
- MJDLFQHBYYIXQF-UHFFFAOYSA-N 4-(5-chloro-4-methyl-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C2=CC=C(Cl)C(C)=C2CC1C1=CNC(=S)N1 MJDLFQHBYYIXQF-UHFFFAOYSA-N 0.000 description 1
- LVOYOVOGCKAAQM-UHFFFAOYSA-N 4-(5-methyl-2,3-dihydro-1h-inden-2-yl)-1,3-dihydroimidazole-2-thione Chemical compound C1C2=CC(C)=CC=C2CC1C1=CNC(=S)N1 LVOYOVOGCKAAQM-UHFFFAOYSA-N 0.000 description 1
- GGVZPCFHQLCJGY-UHFFFAOYSA-N 4-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-7-yl)-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1C1CCC2=CC=CC=C2CC1 GGVZPCFHQLCJGY-UHFFFAOYSA-N 0.000 description 1
- CTNNXIMJMTZSQS-UHFFFAOYSA-N 4-[(2,3-dimethylcyclopent-2-en-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C1CC(C)=C(C)C1CC1=CNC(=O)N1 CTNNXIMJMTZSQS-UHFFFAOYSA-N 0.000 description 1
- PJGHNUBPISFLTJ-UHFFFAOYSA-N 4-[(2-bromo-3-methylcyclopent-2-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC(C)=C(Br)C1CC1=CNC(=S)N1 PJGHNUBPISFLTJ-UHFFFAOYSA-N 0.000 description 1
- YQPCBMZIHBLGQX-UHFFFAOYSA-N 4-[(2-bromocyclopent-2-en-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound BrC1=CCCC1CC1=CNC(=O)N1 YQPCBMZIHBLGQX-UHFFFAOYSA-N 0.000 description 1
- PISVNKIFFBJZFI-UHFFFAOYSA-N 4-[(2-chlorocyclopent-2-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound ClC1=CCCC1CC1=CNC(=S)N1 PISVNKIFFBJZFI-UHFFFAOYSA-N 0.000 description 1
- RPGASCMQRITAAV-UHFFFAOYSA-N 4-[(2-ethenylcyclopent-2-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C=CC1=CCCC1CC1=CNC(=S)N1 RPGASCMQRITAAV-UHFFFAOYSA-N 0.000 description 1
- NOFBDYWKJWJWAW-UHFFFAOYSA-N 4-[(2-ethyl-3-methylcyclopent-2-en-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound CCC1=C(C)CCC1CC1=CNC(=O)N1 NOFBDYWKJWJWAW-UHFFFAOYSA-N 0.000 description 1
- DCTZFBHBYBMZIZ-UHFFFAOYSA-N 4-[(2-ethylcyclohex-2-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound CCC1=CCCCC1CC1=CNC(=S)N1 DCTZFBHBYBMZIZ-UHFFFAOYSA-N 0.000 description 1
- YDJOUXUDRKACSG-UHFFFAOYSA-N 4-[(2-ethylcyclopent-2-en-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound CCC1=CCCC1CC1=CNC(=O)N1 YDJOUXUDRKACSG-UHFFFAOYSA-N 0.000 description 1
- NQZBOYKOWKMWOT-UHFFFAOYSA-N 4-[(2-methyl-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound CC1CC2=CC=CC=C2C1CC1=CNC(=S)N1 NQZBOYKOWKMWOT-UHFFFAOYSA-N 0.000 description 1
- HQHXJKHZOLKOQU-UHFFFAOYSA-N 4-[(2-methylcyclohex-2-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound CC1=CCCCC1CC1=CNC(=S)N1 HQHXJKHZOLKOQU-UHFFFAOYSA-N 0.000 description 1
- ZTIIJXCINHUOIJ-UHFFFAOYSA-N 4-[(2-phenylcyclopent-2-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1C(C=2C=CC=CC=2)=CCC1 ZTIIJXCINHUOIJ-UHFFFAOYSA-N 0.000 description 1
- CRWFSLTYSWJNDG-UHFFFAOYSA-N 4-[(2-thiophen-2-ylcyclopent-2-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1C(C=2SC=CC=2)=CCC1 CRWFSLTYSWJNDG-UHFFFAOYSA-N 0.000 description 1
- IQKPLJMJMITIQI-UHFFFAOYSA-N 4-[(3,4-dimethylcyclohex-3-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC(C)=C(C)CC1CC1=CNC(=S)N1 IQKPLJMJMITIQI-UHFFFAOYSA-N 0.000 description 1
- PNMFZNXLDZSULU-UHFFFAOYSA-N 4-[(3-ethylcyclopent-2-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC(CC)=CC1CC1=CNC(=S)N1 PNMFZNXLDZSULU-UHFFFAOYSA-N 0.000 description 1
- CBJPLWVHWXYUEG-UHFFFAOYSA-N 4-[(3-methyl-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C12=CC=CC=C2C(C)CC1CC1=CNC(=O)N1 CBJPLWVHWXYUEG-UHFFFAOYSA-N 0.000 description 1
- XAHJMEPTRQPPDZ-UHFFFAOYSA-N 4-[(3-methyl-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C12=CC=CC=C2C(C)CC1CC1=CNC(=S)N1 XAHJMEPTRQPPDZ-UHFFFAOYSA-N 0.000 description 1
- LDJXTXUFRFCLAI-UHFFFAOYSA-N 4-[(3-methylcyclopent-2-en-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C1CC(C)=CC1CC1=CNC(=O)N1 LDJXTXUFRFCLAI-UHFFFAOYSA-N 0.000 description 1
- VDERHMOKWVJRGR-UHFFFAOYSA-N 4-[(3-methylcyclopent-2-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC(C)=CC1CC1=CNC(=S)N1 VDERHMOKWVJRGR-UHFFFAOYSA-N 0.000 description 1
- JSCZLVPGUAGBMO-UHFFFAOYSA-N 4-[(4,7-dimethyl-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC=2C(C)=CC=C(C)C=2C1CC1=CNC(=S)N1 JSCZLVPGUAGBMO-UHFFFAOYSA-N 0.000 description 1
- PANAAKKEHTVLTA-UHFFFAOYSA-N 4-[(4-bromo-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC=2C(Br)=CC=CC=2C1CC1=CNC(=S)N1 PANAAKKEHTVLTA-UHFFFAOYSA-N 0.000 description 1
- XCIMERSMCODSNH-UHFFFAOYSA-N 4-[(4-chloro-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC=2C(Cl)=CC=CC=2C1CC1=CNC(=S)N1 XCIMERSMCODSNH-UHFFFAOYSA-N 0.000 description 1
- OMNCSCHMANJUNU-UHFFFAOYSA-N 4-[(4-ethylcyclohex-3-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC(CC)=CCC1CC1=CNC(=S)N1 OMNCSCHMANJUNU-UHFFFAOYSA-N 0.000 description 1
- VPNKDUUPSNQQGG-UHFFFAOYSA-N 4-[(4-ethynylcyclohex-3-en-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1CC1CC=C(C#C)CC1 VPNKDUUPSNQQGG-UHFFFAOYSA-N 0.000 description 1
- RHKUZXZFCDKEEH-UHFFFAOYSA-N 4-[(4-fluoro-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC=2C(F)=CC=CC=2C1CC1=CNC(=S)N1 RHKUZXZFCDKEEH-UHFFFAOYSA-N 0.000 description 1
- SQLJPGNOHKFTOT-UHFFFAOYSA-N 4-[(4-methyl-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C1CC=2C(C)=CC=CC=2C1CC1=CNC(=O)N1 SQLJPGNOHKFTOT-UHFFFAOYSA-N 0.000 description 1
- BLRBZDCXVPYYDT-UHFFFAOYSA-N 4-[(4-methyl-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC=2C(C)=CC=CC=2C1CC1=CNC(=S)N1 BLRBZDCXVPYYDT-UHFFFAOYSA-N 0.000 description 1
- JJSFMTIFGPADFP-UHFFFAOYSA-N 4-[(5-bromo-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C1CC2=CC(Br)=CC=C2C1CC1=CNC(=O)N1 JJSFMTIFGPADFP-UHFFFAOYSA-N 0.000 description 1
- LEGBCHROXWLSQY-UHFFFAOYSA-N 4-[(5-bromo-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC2=CC(Br)=CC=C2C1CC1=CNC(=S)N1 LEGBCHROXWLSQY-UHFFFAOYSA-N 0.000 description 1
- BTKVKWGSLGYMHH-UHFFFAOYSA-N 4-[(5-chloro-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC2=CC(Cl)=CC=C2C1CC1=CNC(=S)N1 BTKVKWGSLGYMHH-UHFFFAOYSA-N 0.000 description 1
- UFUOGALEIPSDPK-UHFFFAOYSA-N 4-[(5-fluoro-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C1CC2=CC(F)=CC=C2C1CC1=CNC(=O)N1 UFUOGALEIPSDPK-UHFFFAOYSA-N 0.000 description 1
- BOPDQOBXNZFDIV-UHFFFAOYSA-N 4-[(5-fluoro-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC2=CC(F)=CC=C2C1CC1=CNC(=S)N1 BOPDQOBXNZFDIV-UHFFFAOYSA-N 0.000 description 1
- UTGXUWFMLXJTBK-UHFFFAOYSA-N 4-[(5-methoxy-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C1CC2=CC(OC)=CC=C2C1CC1=CNC(=O)N1 UTGXUWFMLXJTBK-UHFFFAOYSA-N 0.000 description 1
- GKDVBXJWEINGOV-UHFFFAOYSA-N 4-[(5-methoxy-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC2=CC(OC)=CC=C2C1CC1=CNC(=S)N1 GKDVBXJWEINGOV-UHFFFAOYSA-N 0.000 description 1
- PEPYSONXSGNTGO-UHFFFAOYSA-N 4-[(5-methyl-3,6-dihydro-2h-pyran-2-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound O1CC(C)=CCC1CC1=CNC(=S)N1 PEPYSONXSGNTGO-UHFFFAOYSA-N 0.000 description 1
- JOJXFSUMMCLVMG-UHFFFAOYSA-N 4-[(6-fluoro-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C12=CC(F)=CC=C2CCC1CC1=CNC(=S)N1 JOJXFSUMMCLVMG-UHFFFAOYSA-N 0.000 description 1
- KIQPXDYPZPFJBH-UHFFFAOYSA-N 4-[(6-methoxy-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C12=CC(OC)=CC=C2CCC1CC1=CNC(=O)N1 KIQPXDYPZPFJBH-UHFFFAOYSA-N 0.000 description 1
- QYOYMSSDPHXBFT-UHFFFAOYSA-N 4-[(6-methoxy-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C12=CC(OC)=CC=C2CCC1CC1=CNC(=S)N1 QYOYMSSDPHXBFT-UHFFFAOYSA-N 0.000 description 1
- KXSNZCDWVZSMBV-UHFFFAOYSA-N 4-[(6-methyl-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazol-2-one Chemical compound C12=CC(C)=CC=C2CCC1CC1=CNC(=O)N1 KXSNZCDWVZSMBV-UHFFFAOYSA-N 0.000 description 1
- YKPXQRAWWCPDJQ-UHFFFAOYSA-N 4-[(6-methyl-2,3-dihydro-1h-inden-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C12=CC(C)=CC=C2CCC1CC1=CNC(=S)N1 YKPXQRAWWCPDJQ-UHFFFAOYSA-N 0.000 description 1
- VSGHDIJVAIZGCT-UHFFFAOYSA-N 4-[(8-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1=2C(Cl)=CC=CC=2CCCC1CC1=CNC(=S)N1 VSGHDIJVAIZGCT-UHFFFAOYSA-N 0.000 description 1
- SAHGGNYDPWPNGR-UHFFFAOYSA-N 4-[2-methyl-5-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]cyclopenten-1-yl]benzonitrile Chemical compound C1CC(C)=C(C=2C=CC(=CC=2)C#N)C1CC1=CNC(=S)N1 SAHGGNYDPWPNGR-UHFFFAOYSA-N 0.000 description 1
- VXRGGSIKFFBQLI-UHFFFAOYSA-N 4-[2-tri(propan-2-yl)silyloxyethyl]cyclohexan-1-one Chemical compound CC(C)[Si](C(C)C)(C(C)C)OCCC1CCC(=O)CC1 VXRGGSIKFFBQLI-UHFFFAOYSA-N 0.000 description 1
- QLIWOHMGYAIBPQ-UHFFFAOYSA-N 4-[5-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]cyclopenten-1-yl]benzonitrile Chemical compound N1C(=S)NC=C1CC1C(C=2C=CC(=CC=2)C#N)=CCC1 QLIWOHMGYAIBPQ-UHFFFAOYSA-N 0.000 description 1
- IGEQJXDJMYMIFJ-JTQLQIEISA-N 4-[[(1s)-2,3-dihydro-1h-inden-1-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound N1C(=S)NC=C1C[C@H]1C2=CC=CC=C2CC1 IGEQJXDJMYMIFJ-JTQLQIEISA-N 0.000 description 1
- LAYUWXBZFCIYIY-UHFFFAOYSA-N 4-[[2-(2,3,5-trifluorophenyl)cyclopent-2-en-1-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound FC1=CC(F)=C(F)C(C=2C(CCC=2)CC=2NC(=S)NC=2)=C1 LAYUWXBZFCIYIY-UHFFFAOYSA-N 0.000 description 1
- UAGKMOLXJCYXAZ-UHFFFAOYSA-N 4-[[2-(2,4-difluorophenyl)cyclopent-2-en-1-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound FC1=CC(F)=CC=C1C1=CCCC1CC1=CNC(=S)N1 UAGKMOLXJCYXAZ-UHFFFAOYSA-N 0.000 description 1
- DRTQTZQABLVWDD-UHFFFAOYSA-N 4-[[2-(2-fluorophenyl)cyclopent-2-en-1-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound FC1=CC=CC=C1C1=CCCC1CC1=CNC(=S)N1 DRTQTZQABLVWDD-UHFFFAOYSA-N 0.000 description 1
- KQPGBPJAJPSTGF-UHFFFAOYSA-N 4-[[2-(3,4-difluorophenyl)cyclopent-2-en-1-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1=C(F)C(F)=CC=C1C1=CCCC1CC1=CNC(=S)N1 KQPGBPJAJPSTGF-UHFFFAOYSA-N 0.000 description 1
- ONTGWIJOIHBMIB-UHFFFAOYSA-N 4-[[2-(3-fluorophenyl)cyclopent-2-en-1-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound FC1=CC=CC(C=2C(CCC=2)CC=2NC(=S)NC=2)=C1 ONTGWIJOIHBMIB-UHFFFAOYSA-N 0.000 description 1
- RUWMNZNSYXRIEB-UHFFFAOYSA-N 4-[[2-(4-fluorophenyl)-3-methylcyclohex-2-en-1-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CCC(C)=C(C=2C=CC(F)=CC=2)C1CC1=CNC(=S)N1 RUWMNZNSYXRIEB-UHFFFAOYSA-N 0.000 description 1
- ZIWZICQRTAMHER-UHFFFAOYSA-N 4-[[2-(4-fluorophenyl)-3-propan-2-ylcyclopent-2-en-1-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC(C(C)C)=C(C=2C=CC(F)=CC=2)C1CC1=CNC(=S)N1 ZIWZICQRTAMHER-UHFFFAOYSA-N 0.000 description 1
- CEKAYAJAOYIVJM-UHFFFAOYSA-N 4-[[2-(4-fluorophenyl)cyclopent-2-en-1-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1=CC(F)=CC=C1C1=CCCC1CC1=CNC(=S)N1 CEKAYAJAOYIVJM-UHFFFAOYSA-N 0.000 description 1
- IVIRKCUXYWXQQP-UHFFFAOYSA-N 4-[[2-(5-chlorothiophen-2-yl)cyclopent-2-en-1-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound S1C(Cl)=CC=C1C1=CCCC1CC1=CNC(=S)N1 IVIRKCUXYWXQQP-UHFFFAOYSA-N 0.000 description 1
- DXXHLYOEXIQKTB-UHFFFAOYSA-N 4-[[3-cyclopropyl-2-(4-fluorophenyl)cyclopent-2-en-1-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1=CC(F)=CC=C1C1=C(C2CC2)CCC1CC1=CNC(=S)N1 DXXHLYOEXIQKTB-UHFFFAOYSA-N 0.000 description 1
- ZSUIIOHCCSPTNP-UHFFFAOYSA-N 4-[[3-methyl-2-(2-nitrophenyl)cyclopent-2-en-1-yl]methyl]-1,3-dihydroimidazole-2-thione Chemical compound C1CC(C)=C(C=2C(=CC=CC=2)[N+]([O-])=O)C1CC1=CNC(=S)N1 ZSUIIOHCCSPTNP-UHFFFAOYSA-N 0.000 description 1
- FOGZYWOLOPDLTP-UHFFFAOYSA-N 4-methyl-2-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1C2=CC=CC=C2C(C)CC1CC1=CNC(=S)N1 FOGZYWOLOPDLTP-UHFFFAOYSA-N 0.000 description 1
- SRLHDEROUKFEMJ-UHFFFAOYSA-N 4-methyl-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2C(C)CCC(=O)C2=C1 SRLHDEROUKFEMJ-UHFFFAOYSA-N 0.000 description 1
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 1
- CYUYWRBAYDTYIH-UHFFFAOYSA-N 5-(1,2,3,4,5,6-hexahydropentalen-1-ylmethyl)-1h-imidazole Chemical compound C1CC(CCC2)=C2C1CC1=CNC=N1 CYUYWRBAYDTYIH-UHFFFAOYSA-N 0.000 description 1
- KHWVTSPEKQKARQ-UHFFFAOYSA-N 5-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1h-imidazole Chemical compound C1CC2=CC=CC=C2CC1CC1=CNC=N1 KHWVTSPEKQKARQ-UHFFFAOYSA-N 0.000 description 1
- OTDHLPUTOHIFHP-UHFFFAOYSA-N 5-(2,3,4,4a,5,6,7,8-octahydronaphthalen-2-ylmethyl)-1h-imidazole Chemical compound C1CC2CCCCC2=CC1CC1=CNC=N1 OTDHLPUTOHIFHP-UHFFFAOYSA-N 0.000 description 1
- WCTNSXXQDZNCCU-UHFFFAOYSA-N 5-(4,5,6,7-tetrahydro-1-benzothiophen-5-ylmethyl)-1h-imidazole Chemical compound C1CC=2SC=CC=2CC1CC1=CNC=N1 WCTNSXXQDZNCCU-UHFFFAOYSA-N 0.000 description 1
- DAYVHTFGUBWNSK-UHFFFAOYSA-N 5-[(3-ethynylcyclohex-3-en-1-yl)methyl]-1h-imidazole Chemical compound C1C(C#C)=CCCC1CC1=CNC=N1 DAYVHTFGUBWNSK-UHFFFAOYSA-N 0.000 description 1
- KHWVTSPEKQKARQ-NSHDSACASA-N 5-[[(2s)-1,2,3,4-tetrahydronaphthalen-2-yl]methyl]-1h-imidazole Chemical compound C([C@@H]1CC2=CC=CC=C2CC1)C1=CNC=N1 KHWVTSPEKQKARQ-NSHDSACASA-N 0.000 description 1
- BKDMFWDWYWOQIJ-UHFFFAOYSA-N 5-[[5-(oxan-2-yloxy)-2,3-dihydro-1h-inden-1-yl]methyl]-1h-imidazole Chemical compound C=1NC=NC=1CC(C1=CC=2)CCC1=CC=2OC1CCCCO1 BKDMFWDWYWOQIJ-UHFFFAOYSA-N 0.000 description 1
- AXUVBHSQWRRJSD-UHFFFAOYSA-N 5-fluoro-2,3-dihydro-1h-indene-1-carboxylic acid Chemical compound FC1=CC=C2C(C(=O)O)CCC2=C1 AXUVBHSQWRRJSD-UHFFFAOYSA-N 0.000 description 1
- ZRKQOVXGDIZYDS-UHFFFAOYSA-N 5-hydroxy-2,3-dihydroinden-1-one Chemical compound OC1=CC=C2C(=O)CCC2=C1 ZRKQOVXGDIZYDS-UHFFFAOYSA-N 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- OPRZIAMAZGZMCH-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-benzo[7]annulene-7-carbaldehyde Chemical compound C1CC(C=O)CCC2=CC=CC=C21 OPRZIAMAZGZMCH-UHFFFAOYSA-N 0.000 description 1
- JIAKIQWNYAZUJD-UHFFFAOYSA-N 6,7-dihydro-5h-quinolin-8-one Chemical compound C1=CN=C2C(=O)CCCC2=C1 JIAKIQWNYAZUJD-UHFFFAOYSA-N 0.000 description 1
- MVZRMHSDORWTSD-UHFFFAOYSA-N 6-(1h-imidazol-5-ylmethyl)-2,3,4,6,7,8-hexahydro-1h-quinolin-5-one Chemical compound C1CC(NCCC2)=C2C(=O)C1CC1=CNC=N1 MVZRMHSDORWTSD-UHFFFAOYSA-N 0.000 description 1
- ISYIUYRWUINXCB-UHFFFAOYSA-N 6-(1h-imidazol-5-ylmethyl)-5,6,7,8-tetrahydroquinoline Chemical compound C1CC2=NC=CC=C2CC1CC1=CNC=N1 ISYIUYRWUINXCB-UHFFFAOYSA-N 0.000 description 1
- DPLUUXLJOAQEIR-UHFFFAOYSA-N 6-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]-2,3,4,6,7,8-hexahydro-1h-quinolin-5-one Chemical compound C1CC(NCCC2)=C2C(=O)C1CC1=CNC(=S)N1 DPLUUXLJOAQEIR-UHFFFAOYSA-N 0.000 description 1
- WGTYHINFIDRCEU-UHFFFAOYSA-N 6-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]-7,8-dihydro-6h-quinolin-5-one Chemical compound C1CC2=NC=CC=C2C(=O)C1CC1=CNC(=S)N1 WGTYHINFIDRCEU-UHFFFAOYSA-N 0.000 description 1
- BEVVUJBVEXJGKM-UHFFFAOYSA-N 6-amino-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(N)=CC=C21 BEVVUJBVEXJGKM-UHFFFAOYSA-N 0.000 description 1
- LVUUCFIQQHEFEJ-UHFFFAOYSA-N 6-fluoro-2,3-dihydroinden-1-one Chemical compound FC1=CC=C2CCC(=O)C2=C1 LVUUCFIQQHEFEJ-UHFFFAOYSA-N 0.000 description 1
- YKERATSJKUQENY-UHFFFAOYSA-N 6-hydroxy-2-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CC2=CC(O)=CC=C2C(=O)C1CC1=CNC(=S)N1 YKERATSJKUQENY-UHFFFAOYSA-N 0.000 description 1
- FNSQPQKPPGALFA-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(O)=CC=C21 FNSQPQKPPGALFA-UHFFFAOYSA-N 0.000 description 1
- DOXALDISRDZGNV-UHFFFAOYSA-N 7-methyl-2,3-dihydroinden-1-one Chemical compound CC1=CC=CC2=C1C(=O)CC2 DOXALDISRDZGNV-UHFFFAOYSA-N 0.000 description 1
- SDCBOHYQOCGUTM-UHFFFAOYSA-N 8-(hydroxymethyl)-1,2,3,4-tetrahydronaphthalen-1-ol Chemical compound C1CCC(O)C2=C1C=CC=C2CO SDCBOHYQOCGUTM-UHFFFAOYSA-N 0.000 description 1
- SALAJSGMTLXQNG-UHFFFAOYSA-N 8-fluoro-2-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1C=2C(F)=CC=CC=2CCC1CC1=CNC(=S)N1 SALAJSGMTLXQNG-UHFFFAOYSA-N 0.000 description 1
- YKCVICFJPMBHIW-UHFFFAOYSA-N 8-methyl-2-[(2-sulfanylidene-1,3-dihydroimidazol-4-yl)methyl]-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1C=2C(C)=CC=CC=2CCC1CC1=CNC(=S)N1 YKCVICFJPMBHIW-UHFFFAOYSA-N 0.000 description 1
- ACEWUDFEONXYQH-UHFFFAOYSA-N 8-methyl-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=C1C=CC=C2C ACEWUDFEONXYQH-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ARKXIESGLMBVEI-UHFFFAOYSA-N CC=CC1=CCCC1CC1=CNC(=S)N1 Chemical compound CC=CC1=CCCC1CC1=CNC(=S)N1 ARKXIESGLMBVEI-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229910013684 LiClO 4 Inorganic materials 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- URZGXEJUEGZVTA-UHFFFAOYSA-N [5-(2-phenylmethoxyethyl)cyclohexen-1-yl]methanol Chemical compound C1C(CO)=CCCC1CCOCC1=CC=CC=C1 URZGXEJUEGZVTA-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- PNPBGYBHLCEVMK-UHFFFAOYSA-N benzylidene(dichloro)ruthenium;tricyclohexylphosphanium Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-N 0.000 description 1
- UCGFRIAOVLXVKL-UHFFFAOYSA-N benzylthiourea Chemical class NC(=S)NCC1=CC=CC=C1 UCGFRIAOVLXVKL-UHFFFAOYSA-N 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- MXOSTENCGSDMRE-UHFFFAOYSA-N butyl-chloro-dimethylsilane Chemical compound CCCC[Si](C)(C)Cl MXOSTENCGSDMRE-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 1
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- QLSFMYCHPVOSCD-UHFFFAOYSA-N cleroindicin B Natural products OCCC1(O)CCC(=O)CC1 QLSFMYCHPVOSCD-UHFFFAOYSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical class OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- PQANGXXSEABURG-UHFFFAOYSA-N cyclohexenol Natural products OC1CCCC=C1 PQANGXXSEABURG-UHFFFAOYSA-N 0.000 description 1
- ADLKZHGHNJBOOC-UHFFFAOYSA-N cyclopent-3-en-1-ylmethanol Chemical compound OCC1CC=CC1 ADLKZHGHNJBOOC-UHFFFAOYSA-N 0.000 description 1
- XVSYDLITVYBCBD-UHFFFAOYSA-N cyclopent-3-ene-1-carboxylic acid Chemical compound OC(=O)C1CC=CC1 XVSYDLITVYBCBD-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- DLLJVQNYBYOKGS-UHFFFAOYSA-N ethoxyethane;pentane Chemical compound CCCCC.CCOCC DLLJVQNYBYOKGS-UHFFFAOYSA-N 0.000 description 1
- IMPOMZPLABATQT-UHFFFAOYSA-N ethyl 2-(4,5-difluoro-1-hydroxy-2,3-dihydroinden-1-yl)acetate Chemical compound C1=CC(F)=C(F)C2=C1C(CC(=O)OCC)(O)CC2 IMPOMZPLABATQT-UHFFFAOYSA-N 0.000 description 1
- ZEWVCTHJAJZNDZ-UHFFFAOYSA-N ethyl 2-(4,5-difluoro-2,3-dihydro-1h-inden-1-yl)acetate Chemical compound C1=CC(F)=C(F)C2=C1C(CC(=O)OCC)CC2 ZEWVCTHJAJZNDZ-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical class II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- ZUBZATZOEPUUQF-UHFFFAOYSA-N isopropylhexane Natural products CCCCCCC(C)C ZUBZATZOEPUUQF-UHFFFAOYSA-N 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940063711 lasix Drugs 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 1
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- DQDWATOXYCARFV-UHFFFAOYSA-M magnesium;2-methanidylpropane;bromide Chemical compound [Mg+2].[Br-].CC(C)[CH2-] DQDWATOXYCARFV-UHFFFAOYSA-M 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- YCCXQARVHOPWFJ-UHFFFAOYSA-M magnesium;ethane;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C YCCXQARVHOPWFJ-UHFFFAOYSA-M 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- GWGVDNZFTPIGDY-UHFFFAOYSA-M magnesium;ethyne;chloride Chemical compound [Mg+2].[Cl-].[C-]#C GWGVDNZFTPIGDY-UHFFFAOYSA-M 0.000 description 1
- WQMNNHNWITXOAH-UHFFFAOYSA-M magnesium;prop-1-ene;bromide Chemical compound [Mg+2].[Br-].CC=[CH-] WQMNNHNWITXOAH-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- HGMSCFRQKUQYIR-UHFFFAOYSA-N methyl 1-ethyl-2-oxo-5-(2-phenylmethoxyethyl)cyclohexane-1-carboxylate Chemical compound C1CC(=O)C(CC)(C(=O)OC)CC1CCOCC1=CC=CC=C1 HGMSCFRQKUQYIR-UHFFFAOYSA-N 0.000 description 1
- SIGOIUCRXKUEIG-UHFFFAOYSA-N methyl 2-dimethoxyphosphorylacetate Chemical compound COC(=O)CP(=O)(OC)OC SIGOIUCRXKUEIG-UHFFFAOYSA-N 0.000 description 1
- CZONXBVASYLQAY-UHFFFAOYSA-N methyl 2-hydroxy-5-(2-phenylmethoxyethyl)cyclohexane-1-carboxylate Chemical compound C1CC(O)C(C(=O)OC)CC1CCOCC1=CC=CC=C1 CZONXBVASYLQAY-UHFFFAOYSA-N 0.000 description 1
- SYHFNXOORXGLJD-UHFFFAOYSA-N methyl 4-fluoro-6-methoxy-2,3-dihydro-1h-indene-2-carboxylate Chemical compound COC1=CC(F)=C2CC(C(=O)OC)CC2=C1 SYHFNXOORXGLJD-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- YRRWNBMOJMMXQY-UHFFFAOYSA-N n,n-dimethylimidazole-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1C=CN=C1 YRRWNBMOJMMXQY-UHFFFAOYSA-N 0.000 description 1
- JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 1
- SRBHOMIOZFJDNQ-UHFFFAOYSA-N n-(8-oxo-6,7-dihydro-5h-naphthalen-1-yl)acetamide Chemical compound C1CCC(=O)C2=C1C=CC=C2NC(=O)C SRBHOMIOZFJDNQ-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003418 phenoxybenzamine Drugs 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000000029 referred pain Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- HBEFYGYBMKPNSZ-UHFFFAOYSA-N s-phenyl chloromethanethioate Chemical compound ClC(=O)SC1=CC=CC=C1 HBEFYGYBMKPNSZ-UHFFFAOYSA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001577 simple distillation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000005250 spinal neuron Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- WYPMLDZZYQDJRQ-UHFFFAOYSA-N tert-butyl-dimethyl-[[5-(2-phenylmethoxyethyl)cyclohexen-1-yl]methoxy]silane Chemical compound C1C(CO[Si](C)(C)C(C)(C)C)=CCCC1CCOCC1=CC=CC=C1 WYPMLDZZYQDJRQ-UHFFFAOYSA-N 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003051 thermoreceptor Anatomy 0.000 description 1
- 108091008689 thermoreceptors Proteins 0.000 description 1
- ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 1
- VOBWLFNYOWWARN-UHFFFAOYSA-N thiophen-3-one Chemical compound O=C1CSC=C1 VOBWLFNYOWWARN-UHFFFAOYSA-N 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical compound CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 1
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15332802A | 2002-05-21 | 2002-05-21 | |
PCT/US2003/015441 WO2003099795A1 (en) | 2002-05-21 | 2003-05-16 | 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2b and alpha-2c adrenergic receptors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20045054L NO20045054L (no) | 2005-02-10 |
NO330692B1 true NO330692B1 (no) | 2011-06-14 |
Family
ID=29582081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20045054A NO330692B1 (no) | 2002-05-21 | 2004-11-19 | 4-substituerte imidazol-2-tioner og imidazol-2-oner for behandling av sykdom samt anvendelse av disse for fremstilling av medikament for behandling av sykdom |
Country Status (17)
Country | Link |
---|---|
US (5) | US7091232B2 (pt) |
EP (1) | EP1507767A1 (pt) |
JP (2) | JP2005531581A (pt) |
KR (1) | KR101016151B1 (pt) |
CN (1) | CN1332952C (pt) |
AU (2) | AU2003245286A1 (pt) |
BR (1) | BR0311326A (pt) |
CA (1) | CA2486537C (pt) |
CO (1) | CO5621366A2 (pt) |
IL (1) | IL165280A (pt) |
MX (1) | MXPA04011546A (pt) |
NO (1) | NO330692B1 (pt) |
NZ (1) | NZ536626A (pt) |
PL (1) | PL213028B1 (pt) |
RU (1) | RU2318816C2 (pt) |
WO (1) | WO2003099795A1 (pt) |
ZA (1) | ZA200409333B (pt) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
US6699493B2 (en) | 2000-11-29 | 2004-03-02 | Oculex Pharmaceuticals, Inc. | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
IL148921A0 (en) * | 2002-03-26 | 2002-09-12 | Peptor Ltd | Photo active backbone cyclized somatostatin analogs for optical imaging and photodynamic therapy |
US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7358269B2 (en) * | 2002-05-21 | 2008-04-15 | Allergan, Inc. | 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one |
US7276522B2 (en) * | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7323485B2 (en) * | 2002-05-21 | 2008-01-29 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
PL216373B1 (pl) * | 2002-10-08 | 2014-03-31 | Allergan Inc | Zastosowanie selektywnego agonisty receptora α 2B adrenergicznego lub α 2B/2C adrenergicznego |
FI20022159A0 (fi) * | 2002-12-05 | 2002-12-05 | Orion Corp | Uusia farmaseuttisia yhdisteitä |
FI116292B (fi) * | 2003-01-08 | 2005-10-31 | Juvantia Pharma Ltd Oy | Menetelmä substituoitujen imidatsolijohdannaisten valmistamiseksi ja menetelmässä käytettäviä välituotteita |
US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US20060293359A1 (en) * | 2003-06-25 | 2006-12-28 | Allergan, Inc. | Methods and compositions for the treatment of diabetes |
US7141597B2 (en) * | 2003-09-12 | 2006-11-28 | Allergan, Inc. | Nonsedating α-2 agonists |
US20050059664A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
WO2005039567A1 (en) * | 2003-10-08 | 2005-05-06 | Allergan, Inc. | Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides |
US7183305B2 (en) * | 2003-11-11 | 2007-02-27 | Allergan, Inc. | Process for the synthesis of imidazoles |
US7880017B2 (en) * | 2003-11-11 | 2011-02-01 | Allergan, Inc. | Process for the synthesis of imidazoles |
US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
JP3742863B2 (ja) * | 2004-07-02 | 2006-02-08 | ダイキン工業株式会社 | 空気浄化装置 |
NZ553290A (en) * | 2004-09-24 | 2010-11-26 | Allergan Inc | 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
EP1797043A1 (en) * | 2004-09-24 | 2007-06-20 | Allergan, Inc. | 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists |
JP2008514603A (ja) | 2004-09-24 | 2008-05-08 | アラーガン、インコーポレイテッド | α2アドレナリン作動剤としての4−(ヘテロアリール−メチルおよび置換ヘテロアリール−メチル)−イミダゾール−2−チオン |
KR101202066B1 (ko) | 2004-09-28 | 2012-11-15 | 알러간, 인코포레이티드 | 특이적인 또는 선택적인 알파2 아드레날린성아고니스트로서 작용하는 비치환된 및 치환된4-벤질-1,3-디히드로-이미다졸-2-티온 및 이를 사용하는방법 |
US7390829B2 (en) * | 2005-06-29 | 2008-06-24 | Allergan, Inc. | Alpha-2 adrenergic agonists |
JP2009500409A (ja) * | 2005-06-29 | 2009-01-08 | アラーガン、インコーポレイテッド | 痛みを処置するためのα2アドレナリン作動剤 |
US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
US7700592B2 (en) | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
KR20080039982A (ko) * | 2005-08-25 | 2008-05-07 | 쉐링 코포레이션 | 작용 선택적 알파2c 아드레날린성 수용체 효능제로서의이미다졸 유도체 |
PE20070519A1 (es) | 2005-08-25 | 2007-07-13 | Schering Corp | Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c |
US20070203144A1 (en) * | 2006-01-17 | 2007-08-30 | Allergan, Inc. | Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals |
US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
US7323477B2 (en) * | 2006-02-02 | 2008-01-29 | Allergan, Inc. | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline |
US20090252802A1 (en) * | 2006-04-07 | 2009-10-08 | Chang James N | Compositions Including Relatively Water Insoluble/Unwettable Drugs And Methods For Using Same |
US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US20080153881A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders |
US20120083508A1 (en) | 2006-12-22 | 2012-04-05 | Allergan, Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
US20080153874A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain |
WO2008079728A2 (en) * | 2006-12-22 | 2008-07-03 | Allergan, Inc. | Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain |
US20080153825A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan Inc. | Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders |
US20080153927A1 (en) * | 2006-12-22 | 2008-06-26 | Allergan, Inc. | Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
MX2009008776A (es) | 2007-02-13 | 2009-08-25 | Schering Corp | Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos. |
US8563594B2 (en) | 2007-05-08 | 2013-10-22 | Allergan, Inc. | S1P3 receptor inhibitors for treating pain |
EP2185544B1 (en) | 2007-07-19 | 2014-11-26 | Cymabay Therapeutics, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 for the treatment of diabetes and metabolic disorders |
WO2009020578A1 (en) * | 2007-08-06 | 2009-02-12 | Schering Corporation | Alpha2c adrenoreceptor agonists |
JP5433576B2 (ja) * | 2007-08-15 | 2014-03-05 | アラーガン インコーポレイテッド | アドレナリン作動化合物 |
WO2009052075A2 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Method of treating motor disorders with alpha-2b adrenergic receptor agonists |
WO2009052073A2 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists |
US20100216857A1 (en) * | 2007-10-18 | 2010-08-26 | Luhrs Lauren M B | Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione |
TW201024282A (en) * | 2008-11-20 | 2010-07-01 | Orion Corp | New pharmaceutical compounds |
JP2012518005A (ja) * | 2009-02-13 | 2012-08-09 | アラーガン インコーポレイテッド | 4‐(1‐(3‐(ヒドロキシメチル)‐2‐メチルフェニル)エチル)‐1h‐イミダゾール‐2(3h)‐チオン |
WO2011028621A1 (en) | 2009-08-26 | 2011-03-10 | Allergan, Inc. | Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists |
JP5909185B2 (ja) | 2009-10-01 | 2016-04-26 | シマベイ セラピューティクス, インコーポレーテッド | 置換テトラゾール−1−イルフェノキシメチルチアゾール−2−イルピペリジニルピリミジン塩 |
KR20170095402A (ko) | 2009-11-09 | 2017-08-22 | 알러간, 인코포레이티드 | 모발 성장을 촉진하기 위한 조성물 및 방법 |
NZ731621A (en) | 2009-12-04 | 2019-01-25 | Sunovion Pharmaceuticals Inc | Multicyclic compounds and methods of use thereof |
TR201809456T4 (tr) | 2010-08-16 | 2018-07-23 | Allergan Inc | Alfa-2b adrenerjik reseptör agonistleri olan düzenleyici t hücrelerini aktifleştirme metodu. |
WO2012067941A1 (en) * | 2010-11-16 | 2012-05-24 | Allergan, Inc. | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
TN2010000566A1 (en) | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
ME03782B (me) | 2011-04-08 | 2021-04-20 | Janssen Sciences Ireland Unlimited Co | Derivati pirimidina za tretman virusnih infekcija |
CN107011346B (zh) | 2011-11-09 | 2020-06-16 | 爱尔兰詹森科学公司 | 用于治疗病毒感染的嘌呤衍生物 |
WO2013078151A1 (en) | 2011-11-21 | 2013-05-30 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases |
BR112015000615B1 (pt) | 2012-07-13 | 2022-05-31 | Janssen Sciences Ireland Uc | Purinas macrocíclicas para o tratamento de infecções virais e composição farmacêutica que as compreende |
CN104837840B (zh) | 2012-10-10 | 2017-08-08 | 爱尔兰詹森科学公司 | 用于治疗病毒感染及其他疾病的吡咯并[3,2‑d]嘧啶衍生物 |
AU2013346793B2 (en) | 2012-11-16 | 2018-03-08 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
CA2901280A1 (en) | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Sustained drug delivery implant |
KR102300861B1 (ko) | 2013-02-21 | 2021-09-10 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체 |
JP6336036B2 (ja) | 2013-03-29 | 2018-06-06 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染治療のための大環状デアザプリノン |
JP6377139B2 (ja) | 2013-05-24 | 2018-08-22 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染症およびさらなる疾患の処置のためのピリドン誘導体 |
JP6420074B2 (ja) * | 2013-06-27 | 2018-11-07 | 国立大学法人京都大学 | プテロシン誘導体を含む軟骨欠損、軟骨変性、および/または軟骨菲薄疾患治療剤 |
PL3030563T3 (pl) | 2013-06-27 | 2018-01-31 | Janssen Sciences Ireland Uc | Pochodne pirolo [3,2-d] pirymidyny do leczenia zakażeń wirusowych i innych chorób |
EP2821072A1 (en) * | 2013-07-01 | 2015-01-07 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Pharmacological stimulation to facilitate and restore standing and walking functions in spinal cord disorders |
MX368625B (es) | 2013-07-30 | 2019-10-08 | Janssen Sciences Ireland Uc | Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales. |
WO2018002319A1 (en) | 2016-07-01 | 2018-01-04 | Janssen Sciences Ireland Uc | Dihydropyranopyrimidines for the treatment of viral infections |
KR20190065246A (ko) | 2016-07-29 | 2019-06-11 | 선오비온 파마슈티컬스 인코포레이티드 | 화합물 및 조성물 및 이들의 용도 |
IL264446B1 (en) | 2016-07-29 | 2024-05-01 | Pgi Drug Discovery Llc | Compounds and compositions and their use |
CN109862896A (zh) | 2016-08-03 | 2019-06-07 | 西玛贝医药公司 | 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物 |
ES2912945T3 (es) | 2016-09-29 | 2022-05-30 | Janssen Sciences Ireland Unlimited Co | Profármacos de pirimidina para el tratamiento de infecciones virales y otras enfermedades |
IL268694B2 (en) | 2017-02-16 | 2023-10-01 | Sunovion Pharmaceuticals Inc | Treatment of schizophrenia |
EP3661929B1 (en) | 2017-08-02 | 2021-07-14 | Sunovion Pharmaceuticals Inc. | Isochroman compounds and uses thereof |
WO2019161238A1 (en) | 2018-02-16 | 2019-08-22 | Sunovion Pharmaceuticals Inc. | Salts, crystal forms, and production methods thereof |
TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
DE18205817T1 (de) | 2018-11-13 | 2020-12-24 | Gtx Medical B.V. | Sensor in bekleidung von gliedmassen oder schuhwerk |
AU2020236225A1 (en) | 2019-03-14 | 2021-09-16 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
US11738002B2 (en) | 2020-04-14 | 2023-08-29 | Sunovion Pharmaceuticals Inc. | Methods of treating neurological and psychiatric disorders |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3996366A (en) * | 1973-11-19 | 1976-12-07 | The Boots Company Limited | Thio derivatives of imidazol-1-yl carboxamides |
SU795462A3 (ru) | 1975-03-14 | 1981-01-07 | Эдьт Дьедьесерведьесети Дьяр (Фирма) | Способ получени тиокарбамидныхпРОизВОдНыХ |
US4798834A (en) * | 1987-08-31 | 1989-01-17 | Eli Lilly And Company | Optionally substituted (3β-9,10-didehydro-2,3-dihydro ergoline as serotonergic function enhancement |
US4977174A (en) * | 1989-06-12 | 1990-12-11 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
US5212176A (en) | 1990-06-29 | 1993-05-18 | Abbott Laboratories | R(+)-terazosin |
US5861420A (en) * | 1991-04-05 | 1999-01-19 | G. D. Searle & Co. | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders |
US5164403A (en) * | 1991-04-05 | 1992-11-17 | G. D. Searle & Co. | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders |
EP0626969B1 (en) * | 1992-02-11 | 2000-05-24 | Smithkline Beecham Corporation | CoA-IT AND PAF INHIBITORS |
KR0168978B1 (ko) * | 1995-07-12 | 1999-01-15 | 김종인 | 헤테로고리 접합 티아졸 유도체 |
CA2263353C (en) * | 1996-08-22 | 2002-04-23 | Dong Wha Pharm. Ind. Co., Ltd. | Arylsulfonylimidazolone derivatives as an antitumor agent |
EP1413576A3 (en) | 1997-12-04 | 2004-09-01 | Allergan, Inc. | Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
US6465486B1 (en) | 1999-03-12 | 2002-10-15 | Ortho-Mcneil Pharmaceutical, Inc. | Pyridyl/quinolinyl imidazoles |
TWI283669B (en) | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
GB9915184D0 (en) * | 1999-06-29 | 1999-09-01 | Viral As A | Compounds |
US6313172B1 (en) * | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
US6545182B2 (en) * | 2000-04-13 | 2003-04-08 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
AU2002248284A1 (en) | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
US6534542B2 (en) * | 2001-02-27 | 2003-03-18 | Allergen Sales, Inc. | (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors |
US7276522B2 (en) * | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7141597B2 (en) * | 2003-09-12 | 2006-11-28 | Allergan, Inc. | Nonsedating α-2 agonists |
US7183305B2 (en) | 2003-11-11 | 2007-02-27 | Allergan, Inc. | Process for the synthesis of imidazoles |
-
2003
- 2003-05-14 US US10/437,807 patent/US7091232B2/en not_active Expired - Fee Related
- 2003-05-16 KR KR1020047018823A patent/KR101016151B1/ko not_active IP Right Cessation
- 2003-05-16 CN CNB038175010A patent/CN1332952C/zh not_active Expired - Fee Related
- 2003-05-16 AU AU2003245286A patent/AU2003245286A1/en not_active Abandoned
- 2003-05-16 NZ NZ536626A patent/NZ536626A/en not_active IP Right Cessation
- 2003-05-16 PL PL374223A patent/PL213028B1/pl not_active IP Right Cessation
- 2003-05-16 WO PCT/US2003/015441 patent/WO2003099795A1/en active Application Filing
- 2003-05-16 RU RU2004134559/04A patent/RU2318816C2/ru not_active IP Right Cessation
- 2003-05-16 JP JP2004507452A patent/JP2005531581A/ja active Pending
- 2003-05-16 EP EP03738924A patent/EP1507767A1/en not_active Withdrawn
- 2003-05-16 BR BR0311326-4A patent/BR0311326A/pt not_active IP Right Cessation
- 2003-05-16 CA CA2486537A patent/CA2486537C/en not_active Expired - Fee Related
- 2003-05-16 MX MXPA04011546A patent/MXPA04011546A/es active IP Right Grant
-
2004
- 2004-11-17 IL IL165280A patent/IL165280A/en not_active IP Right Cessation
- 2004-11-19 NO NO20045054A patent/NO330692B1/no not_active IP Right Cessation
- 2004-11-19 ZA ZA200409333A patent/ZA200409333B/xx unknown
- 2004-12-13 CO CO04124455A patent/CO5621366A2/es not_active Application Discontinuation
-
2005
- 2005-06-02 US US11/143,334 patent/US7345077B2/en not_active Expired - Lifetime
-
2006
- 2006-03-09 US US11/371,612 patent/US7419994B2/en not_active Expired - Fee Related
-
2008
- 2008-02-16 US US12/070,297 patent/US8071635B2/en not_active Expired - Fee Related
- 2008-07-25 US US12/180,162 patent/US8063087B2/en not_active Expired - Fee Related
-
2010
- 2010-03-24 AU AU2010201167A patent/AU2010201167B2/en not_active Ceased
- 2010-11-08 JP JP2010249874A patent/JP2011079838A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO330692B1 (no) | 4-substituerte imidazol-2-tioner og imidazol-2-oner for behandling av sykdom samt anvendelse av disse for fremstilling av medikament for behandling av sykdom | |
US7569584B2 (en) | 4-(2-methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2b agonist and methods of using the same | |
US7323485B2 (en) | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds | |
CA2581828A1 (en) | 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | |
US7838545B2 (en) | 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | |
NZ553341A (en) | 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |